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CHRONIC MYELOID LEUKEMIA 
 
Chronic myeloid leukemia (CML) results from an increased and unregulated 
proliferation of myeloid cells in the bone marrow. CML typically evolves in three 
distinct clinical stages: chronic phase, accelerated phase and blast crisis (1). The 
chronic phase lasts several years and is characterized by accumulation of 
myeloid precursors and mature cells in the bone marrow, peripheral blood and 
extramedullary sites. The accelerated phase lasts on average four to six months 
and is characterized by an increase in the frequency of early progenitor cells 
rather than differentiated cells. The blast crisis can last only a few months and is 
characterized by the rapid expansion of myeloid differentiation-arrested blast 
cells and has a poor prognosis (2). 
The cause of CML is a characteristic reciprocal translocation between 
chromosome 9 and 22, t(9;22)(q34;q11), which results in the Philadelphia 
chromosome (Ph) (3, 4). This translocation generates the bcr/abl fusion gene, 
translated into a constitutively active protein kinase BCR/ABL (5). 
 
 
Figure 1. Schematic representation of the translocation that creates the 
Philadelphia chromosome (6). The abl and the bcr genes localize on the long arms of 
chromosome 9 and 22, respectively. The translocation (9;22)(q34;q11) creates a shorter 
chromosome 22 called Philadelphia-chromosome, in which the bcr/abl fusion gene is 
generated. 
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Although the presence of a Ph-chromosome always parallels the presence of a 
bcr/abl rearrangement, there is variability in the type of rearrangement between 
bcr and abl at the molecular level. As a consequence, bcr/abl hybrid genes can 
generate different types of fusion transcripts and proteins, which show a 
preferential but not exclusive association with different leukemia phenotypes (7, 
8). All bcr/abl fusion genes contain a 5’ portion derived from bcr sequences and a 
3’ portion that includes the entire abl gene sequence with the exclusion of the 
first 26 codons, corresponding to the alternative 5’ exons, that normally generate 
two variant protein products denoted as type Ia and Ib (9). The constitutively 
activation of BCR/ABL is due to the fact that BCR acts by causing dimerization of 
the BCR/ABL proteins and in this way promotes a transphosphorylation process 
(10). 
 
 
 
Figure 2. Schematic representation of the various breakpoints in the abl and bcl 
genes and the three different proteins encoded by the bcr/abl fusion gene (From: 
www.cincinnatichildrens.org/svc/alpha/m/molecular-genetics/bcr-testing.htm). The bcr 
and abl genes are shown at the top and the RNA transcripts and corresponding proteins 
below. The arrows show the possible sites of breakage in the bcr and abl genes. 
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There are three separate zones where breakpoints occur in bcr gene on 
chromosome 22, one of these is the central region called M-BCR (major 
breakpoint cluster region), which contains five exons corresponding to bcr exons 
10 to 14 (11, 12). Breaks in the M-BCR nearly always occur in the intron between 
exon e13 and e14 or in the intron between exon e14 and e15. In the first case 
exon 13 is joined to abl exon 2 (e13a2 junction), whereas in the second, bcr exon 
14 is spliced to abl exon 2 (e14a2 junction) (13). The two chimeric mRNAs differ 
by the presence of the bcr exon 14 sequences (75 bp), and the corresponding 
p210 proteins differ by 25 amino acids. 
The second breakpoint location in the bcr gene occurs between exons e1 and e2 
in an area designated the m-BCR (minor breakpoint cluster region) and form a 
bcr/abl transcribed in an e1a2 mRNA encoding a p190 BCR/ABL protein (14, 15). 
This is found in 70% of patients with Ph positive acute lymphoblastic leukemia 
(ALL). Both in vivo and in vitro studies suggest that p190 is characterized by a 
higher transforming activity than p210, and this may explain why p190 is 
preferentially associated with an acute leukemia phenotype (16). 
A third breakpoint location is in the µ-BCR (micro breakpoint cluster region) and 
result in an e19a2 mRNA (17). This transcript contains the same portion of abl 
sequence as the other more common types of bcr/abl transcripts, but includes 
almost all the bcr coding sequences and result in a fusion protein of 230 kDa in 
molecular weight (p230). This type of bcr/abl rearrangement has been often 
associated with a very mild form of CML, denominated Ph-positive neutrophilic 
CML (18). 
 
The function of the ABL and BCR proteins 
 
Both bcr and abl are expressed in cells of various tissues. The abl gene encodes 
a 145-kDa protein belonging to the family of the non-receptor tyrosine kinases 
(TK). ABL protein may be found both at the cytoplasmic and nuclear level (19). In 
order to understand the possible function of ABL, it is important to consider the 
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different domains present in the ABL protein, which represent the basis for its 
interaction with other proteins. 
The N-terminal ABL protein contains SH3 and SH2 domains (SRC homology 
region 3 and 2), that are the docking sites of proteins that contain, respectively, 
proline-rich sequences interacting with an SH3 region and phosphotyrosine 
residues interacting with an SH2 region of partner proteins (20). It is through 
these domains that ABL, like its oncogenic counterpart BCR/ABL, is capable of 
activating the transduction of mitogenic signals (21). The C-terminal end of the 
ABL protein contains a domain of interaction with F-actin (22), through which the 
ABL protein plays a role in the physiology of the cytoskeleton. The ABL protein is 
the only non-receptor tyrosine kinase to possess a DNA binding domain in the C-
terminal region (23). It also contains specific sequences that allow the nuclear 
localization of the protein (NLS) and its nuclear extrusion (NES) (24). 
ABL has been implicated as both a negative and a positive regulator of cell 
growth, depending on its phosphorylation state, level of expression, and cellular 
localization (cytoplasmic or nuclear). Several studies suggest a positive role of 
ABL in cell cycle regulation. In quiescent cells, nuclear ABL is kept in an inactive 
state by binding to the retinoblastoma protein (pRB) (25). Phosphorylation of pRB 
by cyclin D-Cdk4/6 disrupts this complex and result in activation of ABL in S-
phase, during which ABL is able to stimulate the transcriptional activity of factors 
such as CREB and E2F-1 and to promote the activity of RNA polymerase II (26). 
ABL plays a key role at cytoplasmic level in the signalling pathways regulating 
growth factor-induced proliferation. It has been implicated in the TK signaling 
cascade involving the platelet-derived growth factor receptor (PDGFR) and 
downstream signaling through non-receptor TKs (SRC/ABL) important for 
mitogenesis and growth factor-induced Myc expression (27). Phospholipase C 
(PLC)-γ1 is required for the activation of ABL by PDGFR. PLC-γ1 and ABL form a 
complex that is enhanced by PDGF stimulation, but after activation, ABL 
phosphorylates PLC-γ1 and, in turn, negatively modulates its function (28, 29). 
In contrast to the previously described positive role in stimulating proliferation, 
overexpression of wild-type ABL in fibroblasts has been shown to be able to 
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induce cell cycle arrest in the G1 phase (30). The growth inhibitory effect of ABL 
requires nuclear localization of ABL and its TK activity (31). ABL is able to induce 
apoptosis in response to genotoxic stress such as ionizing radiation, which is 
known to activate ABL. Cell lacking ABL can activate cell cycle check points and 
DNA repair, but show defects in apoptosis. This ABL function is dependent on 
the presence of wild-type p53, Rb, and p73 proteins (32). 
 
Figure 3. Schematic representation of the functional domains of BCR and ABL 
proteins. A) Functional domains of the BCR protein. At the NH2-terminal end the BCR 
protein presents the dimerization domain (DD) and tyrosine 177, an important 
autophosphorylation site. The center of the protein has a Rho guanidine exchange factor 
domain. CalB is a lipid-binding domain, and RAC-GAP mediates GTP/GDP exchange on 
Rac proteins. Arrows indicate the breakpoints in the various types of Bcr-Abl fusion 
proteins. B) Functional domains of ABL protein. In the ABL protein the 5’ alternative 
exons and the Src homology domains (SH1-3) form most of the NH2-terminal region. 
The SH1 domain carries the tyrosine kinase function, whereas the SH2 domain interacts 
with phosphotyrosines on other proteins. The center of Abl consists of proline-rich 
regions (PxxP) that are important for interaction with SH3 domains of other proteins. At 
the COOH terminal region, nuclear localization signals (NLS), DNA-binding function 
(DNA-BD), a nuclear export signal (NES), and actin-binding motifs are found. Shown are 
also major phosphorylation sites for ATM, cdc2, and protein kinase C (PKC) as well as 
tyrosine 393, a major autophosphorylation site that regulates kinase activity (33). 
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The bcr gene product is a 160-kDa cytoplasmic protein with several functional 
domains (34). The N-terminal 426 amino acids of BCR, encoded by the first 
exon, are retained in all BCR/ABL fusion protein isoforms. This region contains a 
serine-threonine kinase domain, whose only known substrates are BCR and 
Bap-1, and two serine/threonine-rich regions that bind SH2 domains of other 
protein, including ABL, p190 BCR/ABL, and p210 BCR/ABL (35). The proximal 
SH2-binding domain appears to be important for the transformation of murine 
fibroblasts by BCR/ABL (36). The two key motifs of the first BCR exon are 
tyrosine 177 and the coiled-coil domain contained in amino acids 1 to 63, that 
appears to be important for the dimerization of BCR/ABL, which is crucial for the 
ABL kinase activity (10, 37). Whereas, phophorylated tyrosine 177 forms a 
binding site for growth factor receptor-binding protein (GRB-2) (37). In cells with 
a bcr/abl fusion gene, the BCR/ABL oncoprotein, unlike the normal ABL, has 
enhanced tyrosine kinase activity (38) and is predominantly localized in the 
cytoplasm (39). The tyrosine kinase activity is essential for cell transformation 
(16) and the cytoplasmic localization of BCR/ABL allows the assembly of 
phosphorylated substrates in multiprotein complexes that transmit mitogenic and 
antiapoptotic signals (40). 
 
Effects of BCR/ABL on proliferation and survival of CML cells 
 
BCR/ABL activates numerous signal transduction pathways responsible for 
growth factor independent proliferation and reduced susceptibility to apoptosis of 
these cells. The RAS pathway becomes constitutively activated by alternative 
mechanisms involving the interaction of BCR/ABL with the GRB-2/Gab2 
complex, via the GRB-2-binding site in the BCR portion of BCR/ABL, and the 
recruitment/phosphorylation of the SHC adaptor protein (41, 42). The interaction 
of BCR/ABL with GRB-2/Gab2 and the phosphorylation of SHC lead to enhanced 
activity of the guanosine diphosphate/guanosine triphosphate (GDP/GTP) 
exchange factor SOS, which promotes accumulation of the GTP-bound form of 
RAS. The importance of RAS-dependent signaling for the phenotype of 
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BCR/ABL-expressing cells is supported by the observation that down-regulation 
of this pathway by antisense strategies, expression of dominant-negative 
molecules, or chemical inhibitors suppresses proliferation and sensitize cells to 
apoptotic stimuli (43-45). 
 
 
 
Figure 4. Signaling pathways activated by BCR/ABL fusion protein involved in 
proliferation and survival of CML cells (46). 
 
 
 
The phosphatidylinositol-3 kinase (PI-3K) is another important pathway activated 
by BCR/ABL (47, 48). BCR/ABL interacts indirectly with the p85 regulatory 
subunit of PI-3K (49) via various docking proteins including GRB-2/Gab2 and c-
cbl (50). Activation of the PI-3K pathway triggers an Akt-dependent cascade that 
has critical role in BCR/ABL transformation (51) by regulating the subcellular 
localization or activity of several targets such as BAD, MDM2, IκB-kinase-α, and 
members of Forkhead family of transcription factors (e.g. FKHRL1) (52). 
Phosphorylation of BAD suppresses its pro-apoptotic activity because, when 
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phosphorylated, BAD is sequestered in the cytoplasm in a complex with 14-3-3β 
(53). In BCR/ABL-expressing cells, BAD is cytoplasmic and heavily 
phosphorylated (54). Phosphorylation of MDM2 enhances its nuclear-to-
cytoplasm export, potentially inducing a more efficient degradation of p53 (55, 
56). Phosphorylation of IκB-kinase-α enhances its activity toward IκB, its 
substrate (57). Upon phosphorylation, IκB kinase is subjected to ubiquitination 
and proteasome-dependent degradation, allowing the translocation of p65 
nuclear factor κB (NF-κB) into the nucleus where it functions as a transcription 
factor (58). Thus, the net effect of IκB-kinase-α phosphorylation is enhanced NF-
κB activity, which has been associated with BCR/ABL-dependent transformation 
of primary mouse marrow cells (59). Phosphorylation of the FKHRL1 prevents its 
translocation into the nucleus and its transactivation of genes promoting 
apoptosis or inhibiting cell cycle progression (60, 61). 
Another antiapoptotic pathway activated by BCR/ABL is that one dependent on 
signal transducer and activator of transcription 5 (STAT5) (62-65). STAT5 is 
activated by BCR/ABL via the Src family hematopoietic cell kinase (HcK) (66). 
On interaction with the SH3 and SH2 domains of BCR/ABL, this kinase is 
activated and phosphorylates tyrosine 699 of STAT5B, leading to its 
translocation to the nucleus where it functions as a transcription factor (66). The 
role of STAT5 in BCR/ABL leukemogenesis is likely to depend on transcriptional 
activation of its target genes. A STAT5 target potentially involved in BCR/ABL 
leukemogenesis is the anti-apoptotic protein Bcl-XL (67), which could have a role 
in the reduced susceptibility to apoptosis in BCR/ABL-expressing cells. 
 
Effect of BCR/ABL on CML cells adhesion to bone marrow stroma 
 
Normal hematopoiesis in the bone marrow is regulated by cell-cell, cell-matrix, 
cell-growth factor interactions. A cascade of specific signals is required to initiate 
and control proliferation and differentiation of hematopoietic cells. Under normal 
conditions, a balance exists between self-renewal of pluripotent stem cells, 
maturation of cells to be released from the bone marrow, and cell death. CML 
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cells have a defective capacity to adhere to the bone marrow stroma. This may 
due to the fact that BCR/ABL may form multiprotein complexes with adhesion 
proteins such as paxillin and that is able to bind to F-actin, suggesting a direct 
action on cytoskeleton function (68, 69). Part of the adhesion defect of Ph-
positive hematopoiesis is mediated through abnormalities of phosphatidyl-inositol 
(PI)-linked surface receptors, that are involved in the reduced adhesion capacity 
of CML progenitor to the bone marrow stromal compartment (70). In particular, 
lymphocyte-associated-antigen 3 (LFA 3) has been associated with abrogation of 
immune-mediated control of CML progenitor cells (71). The only know function of 
LFA 3 is to act as the binding ligand for the T cell surface protein CD2. CD2/LFA 
3 adhesive interaction between a subset of human T cells and CD34+ 
hematopoietic progenitors plays a role in controlling the size of the actively 
cycling stem cell pool. Deficient expression of LFA 3 may allow Ph-positive cells 
escape this immune mediated growth regulation. 
 
 
 
Target therapy in CML 
 
Imatinib mesylate (Gleevec, Novartis) was the first active BCR/ABL tyrosine 
kinase inhibitor (TKI). It has been demonstrated to have significant activity in 
treatment of all phases of CML (16, 72). Protein kinases such as ABL have 
evolved highly specialized mechanisms for transitioning between active and 
inactive states. Imatinib binds to the activation loop of ABL kinase outside of a 
highly conserved ATP binding site and traps the kinase in an inactive 
conformation (73). In doing so, imatinib inhibits activity of the kinase and induces 
a complete cytogenetic response in more than 80% of patients with CML in 
chronic phase (74). 
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Figure 5. Mechanism of action of imatinib.  
(From: www.mdconsult.com/das/book/body/225459465-3/0/1492/I4-u1.0-B978-1-4160-
2805-5..50200-7--f4.fig). The constitutively active BCR/ABL tyrosine kinase functions by 
transferring phosphate from ATP to tyrosine residues on various substrates. By 
occupying the ATP binding pocket of the ABL kinase domain, imatinib prevents 
substrate phosphorylation and downstream activation of signals, thus inhibiting the 
leukemogenic effects of BCR/ABL on CML cells. 
 
Even if imatinib is effective in the majority of patients with CML, some patients in 
the chronic phase and a substantial portion of patients in advanced phases are 
resistant or intolerant to imatinib (75-77). One cause of resistance is the 
development of point mutations within the kinase domain of BCR/ABL altering 
imatinib binding. The frequency of BCR/ABL mutations in imatinib-resistant 
patients ranges from 40-90% depending on the CML phase (78-82). More than 
50 distinct point mutations encoding single amino acids substitutions in the 
kinase domain of the bcr/abl gene have been detected in patients with imatinib-
resistant CML. At the protein level, these point mutations result in distorted 
configurations of the ABL kinase-imatinib interface. The result is that ABL is 
unable to adopt the inactive conformation to which imatinib binds (78, 83, 84). 
The impaired interaction between imatinib and ABL kinase as a consequence of 
mutations within the ABL kinase is best exemplified by the T315I mutation, which 
has frequently been detected in patients with imatinib-resistant CML (85). The 
threonine residue at position 315 is located near the ABL catalytic domain in the 
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center of the imatinib binding site, which controls access to a hydrophobic region 
of the enzymatic active site.  
 
 
Figure 6. Locations of residues on Abl kinase corresponding to imatinib-resistant 
mutant forms of Bcr-Abl detected in patients (86). 
 
Other mechanisms of imatinib resistance may include: increased expression of 
BCR/ABL through genomic amplification (87), overexpression of Lyn or other 
Src-family tyrosine kinases (88, 89), or overexpression of drug efflux proteins 
such as P-glycoprotein, that may decrease the intracellular concentration of 
imatinib in CML cells (90). The need for new strategies to treat imatinib-resistant 
CML has stimulated considerable efforts to develop novel BCR/ABL inhibitors. 
Dasatinib (BMS-354825) is a multikinase inhibitor with potent activity against 
BCR/ABL (IC50 <1 nM) and SFKs (IC50 of 0.2-1.1 nM) (91). It has been approved 
by the U.S. Food and Drug Administration (FDA) for the treatment of patients 
with CML following failure of or intolerance to imatinib therapy. Dasatinib is able 
to bind ABL with a greater affinity than imatinib, due at least in part to its ability to 
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recognize multiple states of the enzyme (85, 91-93). It is active against imatinib-
resistant mutant BCR/ABL oncoproteins tested to date, except for T315I (85, 86). 
 
 
 
Figure 7. Imatinib chemical structure compared with other inhibitors able to block 
BCR/ABL function. 
 
 
Nilotinib (AMN107) is a phenylaminopyrimidine derivate that was rationally 
designed to bind to BCR/ABL with a better topographic fit than imatinib, resulting 
in greater potency and less likelihood of resistance mutations (94). Nilotinib is 
approximately 20-30-fold more potent than imatinib against BCR/ABL expressing 
cell lines, but approximately 16-fold less potent than dasatinib (86, 94). In vitro, 
nilotinib inhibited 32 of 33 BCR/ABL mutants (not T315I), although nilotinib has a 
20-25-fold lower potency against some BCR/ABL P-loop mutations, such as 
Y253H, E255K and E255V (86, 95). Other than T315I, nilotinib-resistant 
BCR/ABL mutations commonly affected residues within the P-loop (Y253H, 
E225K and A225V). 
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A potential limitation of these compounds, particularly of dasatinib, is that their 
increased potency may be associated with untoward off-target toxicities, which 
probably relate to their inhibitory activity against a broader range of protein 
kinases than imatinib. For instance, dasatinib, in addition to inhibiting SFKs, is 
also a potent inhibitor of the KIT, PDGFR and ephrin receptor (EPHA2) tyrosine 
kinases, which are directly implicated in hematopoiesis, control of tissue 
interstitial-fluid pressure and angiogenesis (96). 
Carboxyamidotriazole (CAI) is an inhibitor of voltage-independent channel 
mediated calcium influx (97, 98) originally described by our group. CAI is able to 
induce growth inhibition and apoptosis in several tumors (98-100). CAI also has 
anti-angiogenetic activity in vivo, and is able to inhibit the proliferation of human 
umbilical vein endothelial cells (HUVECs) in vitro (101). It has been recently 
shown that CAI induces apoptosis in imatinib-resistant CML cells. CAI inhibits 
BCR/ABL-dependent and –independent signaling pathways and reduce 
phosphorilation of cellular proteins including STAT5 and CrkL (102). 
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EXOSOMES 
 
Cell-to-cell communication is required to coordinate different cell types within 
tissues. Cells may communicate by the release of soluble factors (103), adhesion 
molecule-mediated cell-to-cell interaction, or by tunneling nanotubes that 
establish conduits between cells, allowing the transfer of surface molecules and 
cytoplasmic components (104). Recent studies have shown that cells may also 
communicate by the release of microvesicles (MVs). Two distinct classes of 
vesicles have been described: shedding vesicles and exosomes (105).  
 
Figure 8. Schematic representation of exosome and shedding vesicles formation. 
(a) Release of exosomes. Exosomes accumulate within multivesicular bodies as a result 
of endosome compartmentalization. Exosomes are released by fusion of multivesicular 
bodies with the plasma membrane. (Upper inset) The representative transmission 
electron microscopy (TEM) shows exocytosis of exosomes from the surface of a 
mesenchymal stem cell. (Lower inset) A representative TEM shows a multivesicular 
body within a mesenchymal stem cell. (b) Production of shedding vesicles from the cell 
surface. Shedding vesicles are sorted out from cytoplasm by budding of cell plasma 
membrane in response to cell stimulation. (Left micrograph) The TEM panel shows 
vesicles shed from the surface of an endothelial progenitor cell. (Right micrograph) The 
TEM panel shows an aspect of cell membrane budding in an endothelial progenitor cell 
during microvesicle formation (106). 
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Shedding vesicles are MVs with a size ranging from 100 nm to 1 µm. Formation 
of shedding vesicles takes place from the budding of small cytoplasmic 
protrusions followed by detachment from the cell surface. This process is 
dependent on calcium influx, calpain, and cytoskeleton reorganization (107). 
Exosomes are the smallest vesicles: they have an endocytic origin and are 
release by most cells in culture (108). However, typical exosomes are sometimes 
generally referred to as MVs (109-111), or were initially described as plasma 
membrane vesicles (112) and then later characterized as exosomes (113). 
 
Exosome composition 
 
Exosomes are vesicles with a diameter ranging between 30 and 100 nm (105), 
and with a characteristic cup-shaped morphology. They sediment in sucrose 
gradients in ranges from 1.13 to 1.19 g/ml (108). The protein content of 
exosomes has been extensively analyzed from various cell types and body fluids 
by mass spectrometry, Western blotting, fluorescence-activated cell sorting and 
immuno-electron microscopy (114). Exosome protein composition varies 
depending on the cell type of origin and a unique tissue/cell type signature for 
exosomes was revealed (115). There is also a conserved set of proteins in 
exosomes as a class, independent of their cellular origin. Most of these proteins 
are used as markers to characterize the purified vesicles as exosomes (Table 1). 
Multivescicular body (MVB) biogenesis molecules such as Alix, Tsg101, and 
clathrin are highly associated with exosomes (114). Exosomes also contain heat 
shock proteins, such as the constitutive isoforms of HSC70 and HSP90. These 
ubiquitous proteins are involved in antigen presentation, as they can bind 
antigenic peptides and participate in loading peptides onto MHC molecules (116). 
Another class of cytosolic proteins commonly seen in exosomes includes the 
Rabs, the largest family of small GTPase, which regulate exosome docking and 
membrane fusion (117, 118). In addition to Rabs, exosomes are rich in annexins, 
which aid in membrane trafficking and fusion events (119). Finally, one of the 
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most abundant protein families that is found in exosomes comprises the 
tetraspanins (120). 
Table 1. Characteristic protein markers of exosomes (121) 
a Abbreviations for cell types: B, B cells; DC, dendritic cells; HEK, human embryonic kidney cells; IEC, 
intestinal epithelial cells; Mast, mast cells; M, melanoma cells; MC, mesothelioma cells; Mov, immortalized 
Schwann cells; MVB, multivesicular bodies; P, platelets; Ret, reticulocytes; T, T cells; U, urine 
 
Protein 
  
MW 
(KDa) 
Cell types with 
exosomes containing 
the proteina 
 
Enrichment in 
exosomes  
     
   
Remarks       
             
 
Alix  96 DC, M, U Medium  MVB marker 
 
Annexin II 
 
38 
 
DC, M, IEC, MC 
Mov, U 
 
Low  
 
B7-2 80 DC, B, Mast  High  Not all cells express 
B7-2 
Calnexin  96  Absent in  
exosomes 
Endoplasmic  
Reticulum marker 
CD9 25 DC, IEC, U, P High   
CD63, CD81 50-60 Human: DC, B, IEC High   
Clathrin  192 DC, IEC, B, HEK  Medium   
 
Flotillin-1  
 
48 
 
DC, Mov, U, Ret 
 
Medium  
 
Associated with  
Lipid rafts 
Gi2-α 40 DC, Mov, U, B, Ret Medium   
 
Grp 94(or gp96) 
 
96 
 
 
 
Absent in  
exosomes 
 
Endoplasmic 
reticulum marker 
Hsc 70 70 DC, M, MC, Mov, U 
B, Ret, Mast 
Low   
ICAM-1 90 Mature DC, B Variable,  
Depending on the 
cell type 
 
  
Lamp-1 or 2 90 DC, B Low  Enrichment of 
lamp-1 or lamp-2 on  
exosomes depends  
on the cell type 
MFG-E8 70+ 
60 
DC, IEC, Mov Very high (not 
detectable in cell  
lysates) 
Not all cells express 
MFG-E8 
 
MHC I 
 
47 
 
DC, IEC, MC, U, B 
T, HEK 
 
Medium  
 
 
MHC II 
 
30 (α 
Chain) 
 
 
DC, IEC, B, T, Mast 
 
High  
 
Not all cells express 
MHC II 
Transferrin 
receptor 
90 DC, Mov, Ret Variable, 
depending on the 
cell type  
 
 
Tgs 101 
 
 
44 
 
DC, Mov, U 
 
Medium  
 
MVB marker 
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Several members of this family (including CD9, CD63, CD81 and CD82) are 
highly enriched in exosomes from virtually any cell type. Tetraspanins interact 
with many protein partners, including integrins and MHC molecules, which 
indicates that they are involved in the organization of large molecular complexes 
and membrane subdomains. 
 
 
Figure 9. A graphical representation of the protein composition of exosomes(114). 
 
Limited data are available describing the lipid composition of exosomes. The 
general composition of reticulocyte-derived exosomes is similar to that of the 
plasma membrane of the producing cell (122). The presence of lyso-bis-
phosphatidic acid, a lipid that is enriched in late endocytic compartment, has 
been reported in B-cell-derived exosomes (123). Phosphatidylserine (PS), a lipid 
that is present normally at the cytosolic side of the plasma membrane, is also 
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present, but at low levels, at the surface of exosomes that are derived from 
platelets and dendritic cells (DCs) (105). Finally, internal vesicles of late 
endosomes and exosomes of EBV-transformed B cells are rich in cholesterol, as 
are the plasma-membrane microdomains known as ‘lipid-rafts’ (124). 
 
Biogenesis and release of exosomes 
 
Exosomes originate from the inward budding of the endosomal membrane 
leading to the formation of the MVBs. They are then released into the 
extracellular milieu by fusion of the MVBs with the plasma membrane. 
Accumulating evidence suggests that some components of the molecular 
machinery involved in sorting proteins toward the degradative pathway drive 
membrane invagination in early endosomes, thereby generating the MVBs. 
Central players in this processes are the endosomal sorting complexes required 
for transport (ESCRT) (125, 126). 
 
 
Figure 10. Process of exosome formation and release. Ub, ubiquitin; AP, adaptor 
protein; ESCRT, endosomal sorting complex required for transport; ALIX, ALG-2 
interacting protein X (127). 
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ESCRT complexes deform the endosomal-limiting membrane by specific protein-
protein and protein-lipid interactions, thereby orchestrating inward budding of 
vesicles. ESCRT-0, ESCRT-I and ESCRT-II have ubiquitin-interacting modules 
that are essential for cargo recognition and sorting. Ubiquitinated cargo first binds 
to HRS (hepatocyte growth factor-regulated kinase substrate, a component of 
ESCRT-0) on flat clathrin coats on the endosomal membrane (126). Next, 
ESCRT-I and ESCRT-II are recruited to the membrane, where they cluster the 
ubiquitinated trans-membrane proteins and package them into budding 
exosomes (128). ESCRT-III recruits de-ubiquitinating enzymes to remove 
ubiquitin from cargo proteins before their incorporation into the exosomes, and it 
also recruits Vps4, an ATPase that catalyze the disassembly of all ESCRTs from 
membrane. Another class E Vps protein, Alix (apoptosis-linked gene 2 (ALG-2)-
interacting protein X), acts as a linker between different ESCRT complexes and 
might also play a part of intraluminal vesicle generation (129).  
The coordinated recruitment and utilization of ESCRT machinery after 
ubiquitination is a well-established model of MVB biogenesis and cargo sorting. 
However, recent studies have provided evidence that some exosomal proteins 
are released in an ESCRT-independent manner (130, 131). One of these 
pathways requires the lipid, ceramide (130, 132, 133). Ceramide has many 
structural properties that may facilitate vesicle biogenesis. Ceramides are known 
to induce lateral phase separation and domain formation in model membranes 
(134). In addition, the cone-shaped structure of ceramide may induce 
spontaneous negative curvature in the membrane bilayer promoting membrane 
invagination. Proteins, such as tetraspanins, may partition into these domains. It 
is also possible that tetraspanins are part of the sorting system, as they are 
known to form oligomers by interacting with other tetraspanins and also with a 
variety of trans-membrane and cytosolic proteins (120). There is increasing 
evidence that the clustering of exosomal cargo is an important sorting 
determinant. For example, antibody-induced crosslinking of the transferrin 
receptor in reticulocytes (135), MHC-II in lymphocytes (136) or CD43 in Jurkat T 
cells (131), enhances their secretion in association with exosomes. Furthermore, 
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the addition of multiple homo-oligomerization domains to an acylated reporter 
protein increases its exosomal release (131). The oligomerization of exosomal 
components may lead to recruitment and stabilization of exosomal membrane 
domains. If these grow beyond a critical size, domain-induced budding may be 
triggered and vesicles formed after fission has occurred at the domain 
boundaries (137). There are some examples of proteins that may use such a 
pathway. The melanosomal protein (Pmel17) is sorted to the intraluminal vesicles 
of multivesicular endosomes by a luminal domain-dependent and ESCRT-
independent pathway (138). Furthermore, the exosomal release of CD63, CD82 
and the proteolipid protein (PLP) was not affected after inhibition of class E Vps 
proteins (130, 131). The function of the ESCRT machinery to recruit cargo and to 
deform membrane does not seem to be required in this pathway. 
Exosomes are released both constitutively and in a regulated manner. The 
molecular machinery involved in the exocytic fusion of MVBs to release 
exosomes is still under investigation. One hypothesis is that the regulated 
release of exosomes uses similar mechanisms to those involved in the fusion of 
secretory lysosome with the plasma membrane (139). Calcium ionophores, 
which trigger lysosomal exocytosis (140), stimulate exosome release in many cell 
types, including epithelial cells and the CML cell line K562 (141-145). 
Additionally, a rise in calcium concentration enhances exosome secretion in 
Rab11 overexpressing cells (117).  Rab11 inhibits membrane recycling from the 
recycling compartment and drives membrane proteins to MVBs. Moreover, 
Rab11 facilitate homotypic fusion of MVBs (117). Cellular stress has also been 
shown to stimulate exosome secretion. DNA damage, for instance, activates the 
tumor suppressor p53, which induces the release of exosomes, presumably as a 
mechanism of tumor surveillance or to affect gene expression in adjacent cells 
(146). Finally, other two Rab proteins, Rab27a and Rab27b, have been shown to 
be involved in docking and fusion of MVBs to the plasma membrane, allowing the 
final release of the exosomes in the extracellular space (118). 
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Interaction of MV with target cells 
 
Upon release from their cell of origin, it seems that MVs do not interact with just 
any cell they come into contact with but, rather, only with cells that they 
recognize specifically. For example, the vesicles shed from platelets interact with 
macrophages and endothelial cells, but not with neutrophils (147). Those from 
neutrophils interact with platelets, macrophages and dendritic cells (148-150). 
Also important is the nature of the interaction with the target cell. In some cases, 
it is restricted to the surface and mediated, at least in part, by receptor binding 
(151). In this case, MVs may act as signaling complexes by direct stimulation of 
target cells. MVs derived from platelets, for instance, have an important role in 
coagulation as their phosphatidylserine-enriched membranes provide a surface 
for assembly of clotting factors (152, 153). The coagulation defects seen in Scott 
syndrome, a rare congenital bleeding disorder, depend on defective scrambling 
of membrane phospholipids with an impaired formation of MVs (153). After 
activation, platelets shed MVs coated with tissue factor that may interact with 
macrophages, neutrophils, and other platelets by ligation with molecules 
expressed on the surface of these cells such as P-selectin (154). On the other 
hand, MVs released from neutrophils express activated leukocyte integrin alpha 
M beta2 (Mac-1) that is able to induce platelet activation (155). 
MVs may also act by transferring receptors between cells. The transferring of 
receptors is supported by the observation that bystander B cells rapidly acquire 
antigen receptors from activated B cells by a membrane transfer (156). This 
allows an amplified expansion of the antigen-binding B cells with the ability to 
present a specific antigen to CD4 T cell. A number of other receptors have been 
found to be transferred from one to another cell type. For instance, MVs can 
transfer the adhesion molecule CD41 from platelets to endothelial cells (157) or 
tumor cells (158), conferring pro-adhesive properties to them. MV-mediated 
transfer of Fas ligand from tumor cells induces apoptosis of activated T cells 
favoring tumor immune escape (159). Another recent report showed that tumor 
MVs can transfer an oncogenic form of EGF receptor (EGFR) to cells expressing 
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a wild-type receptor, which then leads to aberrant intracellular signaling by the 
oncogenic receptor and subsequent transformation of the recipient cells (160). 
 
 
 
Figure 11. Schematic representation of mechanisms involved in microvesicle 
(MV)-mediated cell-to-cell communication. (a) MVs may act as a ‘signaling complex’ 
through surface-expressed ligands that directly stimulate the target cells. (b) MVs may 
transfer receptors between cells. (c) MVs may deliver functional proteins or infectious 
particles to target cells. (d) MVs may transfer genetic information via mRNA, microRNA 
(miRNA), or transcription factors from one cell to another (106). 
 
MVs are also able to deliver proteins within the target cells. An example of this 
mechanism is the recent reported MV-mediated transfer of a cell death message 
via encapsulated caspase-1 (161). It has been found that endotoxin-stimulated 
monocytes induce the cell death of vascular smooth muscle cells by releasing 
MVs containing caspase-1. This trans-cellular apoptosis induction pathway 
depends on the function of the delivered caspase-1 within the target cells. It has 
also been suggested that MVs may contribute to dissemination of certain 
infective agents, such as human immunodeficiency virus and prions (162, 163). 
Very interesting is the ability of MVs to deliver mRNAs, which can ultimately 
contribute to the molecular phenotype of target cells. It has been recently shown 
that mRNA incorporated in MVs from glioblastoma cell lines can be delivered to 
normal endothelial cells and generate functional proteins (164). The MVs can 
also contain microRNAs (miRNAs) that are known to control gene expression by 
regulating mRNA turnover (165). Many vesicles transferring mRNAs were shown 
to be released from progenitors of differentiated cells and also from tumor cells 
(152, 166, 167). 
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Role of exosome in antigen presentation 
 
The finding that secreted MVs carry both antigenic material and peptide-MHC 
complexes generated interest on a possible role of MVs in triggering immune 
responses. MVs released by live cells are a possible source of exogenous 
antigens for antigen presenting cells (APC). Exosomes purified from cultured 
tumor cell lines (168) or from ascites of patients with tumors (169) contain tumor 
antigens and can induce the activation of antigen-specific T cells in vitro in the 
presence of recipient dendritic cells (DCs). In addition to whole or partially 
processed antigens, secreted vesicles also display preformed peptide-MHC 
complexes on their surface that can, in certain circumstances, be directly 
presented to T cells. Several groups have reported that DC-derived exosomes 
could induce the activation CD8+ T cell clones, either alone (170-172) or when 
incubated with DCs that express allogenic MHC class I molecules (173, 174), 
which indicates that preformed peptide-MHC class I complexes from exosomes 
are functional. APC-derived exosomes also contain large amounts of MHC class 
II molecules (175, 176) because they originate from late endocytic 
compartments, in which MHC class II molecules reside. APC-derived exosomes 
can directly activate cognate T cell clones or lines (171, 175), or pre-activated 
CD4+ T cells (136), but they need to be captured by recipient DCs to activate 
naïve CD4+ T cells (136, 177, 178). 
 
Role of exosomes in inflammation 
 
Inflammation is sustained by the interaction of various cell types, either directly 
and/or through mediation by cytokines and other soluble factors (179). MVs 
released by various cell type are known to participate as well. Their role can vary 
depending on the stage of the process. At an early stage, the vesicles shed by 
neutrophils stimulate the release of anti-inflammatory factors such as TGFβ1 and 
interleukin-10 from macrophages with reduction of TNFα and interleukin-8 (151, 
180). At later time points, however, MVs can become pro-inflammatory, 
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mediating the transfer of chemokine receptors, such as CCR4 and CCR5, and 
stimulating the release of other mediators, such as interleukin-6 and the 
monocyte chemotactic protein 1 (MCP1), which induce and strengthen 
inflammatory responses (181). MVs seem also play an important role in the 
pathogenesis of various inflammatory diseases, as indicated by their high levels 
in the foci of inflammation. For example, abundant vesicles shed from fibroblast 
seem to stimulate production of metalloproteinases and secretion of cytokines in 
arthritis (181). 
 
Role of MV in tumor progression 
 
The tumor microenvironment of many tumors is highly enriched in MVs released 
not only by the tumor cells but also by macrophages and neutrophils infiltrating 
the host parenchima. The increased number of circulating MVs in patients with 
gastric cancer is correlated with poor prognosis (182). MVs can carry active 
metalloproteinases that may contribute to stromal remodeling and favor tumor 
cell migration and metastasis (183-186). Matrix digestion favors angiogenesis, 
which is of key importance for tumor growth (187). Moreover, pro-angiogenic 
cytokines or mRNAs present inside MVs also stimulate angiogenesis (164). 
Another mechanism by which MVs can reinforce tumor cell growth is by 
triggering a Fas-dependent apoptosis of activated lymphocytes (188). In addition, 
tumor-derived MVs promote expansion and resistance to apoptosis of human 
regulatory T cells (Treg) and upregulate their suppressor function (189). 
Interaction of tumor MVs with Treg may affects peripheral tolerance by tumors and 
supports immune evasion of human cancers. Finally, accumulation of drugs, 
such as doxorubicin and other anti-cancer agents in the membrane of MVs 
decrease their cellular levels and can contribute to the process of drug resistance 
(190). 
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ANGIOGENESIS 
 
Angiogenesis is the formation of new blood vessels from pre-existing 
vasculature. Pro-angiogenic molecules can initiate this process, and anti-
angiogenic molecules can stop it. These molecules with opposite function are 
continuously acting in concert to maintain a quiescent vasculature (191). Various 
signals can trigger a switch that tips this balance in favor of angiogenesis. These 
include metabolic stress, mechanical stress, immune/inflammatory response, and 
genetic mutations (192, 193). 
One of the stimuli that can initiate angiogenesis is the production of proteases in 
stimulated endothelial cells. These proteases degrade the subendothelial 
basement membrane (194). As a consequence, endothelial cells have an 
opening through which to migrate into local tissue, where they proliferate and 
differentiate to form a new vessel. The endothelial cells produce specific growth 
factors, such as platelet-derived growth factor (PDGF) and transforming growth 
factor-β (TGF-β), to attract supporting cells, called pericytes (195). A new highly 
specific basement membrane is subsequently produced, containing collagen IV, 
laminin, perlecan, nidogen, and fibronectin (196). At the end of this process, 
vessels surrounded by membrane and pericytes are mature. Several cytokines 
have been show to be involved in regulation of angiogenic processes. Among 
these, members of the vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) family have a predominant role. 
 
VEGF and VEGF receptor function during angiogenesis 
 
The VEGF ligand family includes six related proteins: VEGF-A, placental growth 
factor (PlGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E (197-201). VEGF-A, PlGF, 
VEGF-B and VEGF-E appear to exert their effects preferentially on vascular 
endothelial cells. VEGF-C and -D, on the other hand, act on lymphatic 
endothelial cells. Structurally, VEGFs are homodimers composed of polypeptide 
chains, which in their overall organization and spacing of cysteine residues are 
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related to PDGF. The original human VEGF (VEGF-A) exists in several isoforms, 
VEGF 121, 165, 189, and 206, which differ in heparin-binding ability (197, 202-
204). The VEGF-A165 isoform appears to be the biologically active form in 
physiological as well as pathological angiogenesis. Hypoxia is an important factor 
in induction of VEGF-A expression (205, 206). In fact, several different elements 
for binding of hypoxia-inducible transcription factors (HIFs) have been identified 
in the VEGF promoter (207). 
The VEGFs bind to three cell surface-expressed receptors, that are structurally 
related. VEGFR-1 and -2 are expressed preferentially on vascular endothelial 
cells (208). During embryogenesis, VEGFR-3 is expressed on vascular and 
lymphatic endothelial cells, but later, expression of this receptor is confined to 
lymphatic endothelium (209). The extracellular domains of these receptors 
contain seven immunoglobulin-like loops; they have a single transmembrane 
spanning domain, and their intracellular domain contain the tyrosine kinase 
activity. The binding of the ligand induces dimerization of the VEGFR receptors, 
which leads to the activation of the kinase (210). 
A number of phosphorylation sites have been described in VEGFR-1 and -2, 
which appear to interact with signal transduction molecules that have been 
assigned more or less critical roles in the establishment of the VEGF-induced 
endothelial cell response (211-214). Proliferation of endothelial cells involves the 
Ras/MAPK pathway. However, at least in certain endothelial cells, downstream 
components in the Ras/MAPK pathway are activated even in the absence of 
active Ras (215). This may occur through activation of phospholipase Cγ (PLCγ) 
that leads to activation of protein kinase C family members, which in turn may 
phosphorylate and activate serine kinases downstream of Ras (216). The 
serine/threonine kinase p38 has been suggested to have an essential role in 
migration of endothelial cells towards VEGF (217). Other signal transduction 
molecules activated downstream of VEGFR are PI3K, that has been implicated in 
cell migration, proliferation and survival, and endothelial nitric oxide synthase 
(eNOS) that induces angiogenesis and increase vascular permeability (218). 
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Figure 12. Schematic illustration of VEGFR-2 signaling. After receptor dimerization, 
several SH2 domain-containing signal transduction molecules (blue) are activated either 
directly by receptor binding, such us PLCγ, VRAP, and Sck, or by indirect mechanisms, 
such as Src and PI3K. A number of downstream signal transduction molecules (green) 
are thereby activated and mediate different pathways leading to cellular functions such 
as cell proliferation, migration, and survival. Activation of PKC plays a crucial role in 
VEGF-A mitogenic signaling via Raf-MEK-ERK pathway. Cell survival signal is mainly 
mediated through PI3K-mediated activation of Akt/PKB. Activation of PI3K, FAK, and 
p38 MAPK is also implicated in cell migration signaling. Bold arrows, positive stimulation; 
bold lines, inhibition; fine arrows, interactions not well established. MAPKAPK2/3, 
MAPK-activating protein kinase-2 and -3 (218). 
 
FGF and FGF receptor function during angiogenesis 
 
There are about twenty-four members of the FGF family (219). All members 
contain heparin/heparan sulfate-binding domains and for at least for some FGFs, 
heparin/heparan sulfate is critical for their biological effect (220). Of the different 
FGF family members, FGF-1 (acidic FGF) and FGF-2 (basic FGF) are 
preferentially implicated in angiogenesis (221). Four related FGF receptor 
tyrosine kinases have been described, which through alternative splicing appear 
in numerous variants (222). It appears that several FGFs bind more than one 
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FGF receptor type with high affinity. FGF receptor-1 (FGFR-1) has been shown 
to be expressed on endothelial cells in vivo and in vitro (223-225). For potent 
activation of receptors by FGF, the ligand has to be presented via heparan 
sulfate or heparin. This presentation may involve the creation of a ternary 
complex involving FGF, heparin/heparan sulfate, and the receptor (226, 227). 
Activation of FGFR-1 lead to autophosphorylation of at least seven tyrosine 
residues (228, 229), which allows more or less stable interaction with several 
different signal transduction molecules. FGF-induced cellular proliferation 
involves several different parallel pathways, initiated via the adaptor molecules 
Shc, FRS2, and Crk. These may converge on the Ras patway. PLCγ and the 
cytoplasmatic tyrosine kinase Src are also known to affect signal transduction in 
the Ras pathway (229). Moreover, Src has been implicated in FGF-induced cell 
migration and differentiation (229). 
 
 
Figure 13. Structure of FGFRs and the major signaling pathways of FGF signal. 
FGFRs contain an extracellular ligand-binding domain, a transmembrane region and a 
highly conserved intracellular signaling domain. Activated FGFRs (red rectangles) 
stimulate multiple pathways such as PLC-γ, Ras-MAP kinase and PI-3 Kinase/AKT 
pathway. In some cells, FGF signaling also phosphorylates the Shc and Src protein. 
Additionally, activation of FGFR3 can stimulate STAT1-p21 pathway in chondrocytes 
(230). 
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Tumor angiogenesis 
 
Angiogenesis is a key element in the pathophysiology of tumor growth and 
metastasis (231). Once a tumor grows beyond approximately 100-200 µm in 
diameter, passive diffusion is no longer able to support malignant cell survival 
and division, and neovascularization becomes essential (232). Hypoxia induces 
vessel growth by signaling through HIFs. These factors induce the production of 
pro-angiogenic compounds such as VEGF, FGF angiopoietin (Ang)-1, and 
various cytokines (233). This destroys the normal balance between pro-
angiogenic and anti-angiogenic factors leading to the ‘angiogenic switch’. 
 
 
Figure 14. The development of new vessels in tumor angiogenesis. (From : 
Siemann DW., Vascular targeting agents. Horizons in Cancer Therapeutics: From Bench 
to Bedside. 2002;3(2):4-15) 
 
Tumor vessels are structurally and functionally abnormal. In contrast to normal 
vessels, tumor vasculature is highly disorganized; vessels are tortuous and 
dilated, with uneven diameter, excessive branching and shunts. This may be due 
to an imbalance in angiogenic regulators, such as VEGF and angiopoietins. 
Consequently, tumor blood flow is chaotic and variable (234), and leads to 
hypoxic and acidic regions in tumors (235). These conditions lower therapeutic 
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effectiveness, modulate the production of angiogenic stimulators and inhibitors, 
and select for cancer cells that are more malignant and metastatic. In addition, 
hypoxia may select for clonal expansion of cells that have lost their apoptotic 
response to hypoxia (236). 
Tumor vessels ultrastructure is also abnormal. Their vessel walls have numerous 
openings, widened interendothelial junctions, and a discontinuous or absent 
besement membrane. In addition, tumor-associated endothelial cells are 
abnormal in shape, growing on top of each other and projecting into the lumen. 
These defects make tumor vessels leaky (237-239). Cytokines and angiogenic 
molecules secreted by cancer and immune cells can modulate the expression of 
cellular adhesion molecules and other surface markers on the tumor 
endothelium. For example, VEGF and tumor necrosis factor-α (TNF-α) up-
regulate, and bFGF and TGF-β1 down-regulate adhesion molecules (240). 
Chaotic blood supply coupled with non-uniform expression of adhesion 
molecules may explain why leukocyte-endothelium interaction is low in tumors 
and why activated lymphocytes adhere non-uniformly to tumor vessels. 
 
In vitro models of angiogenesis: the use of Matrigel 
 
Matrigel is a soluble and sterile extract of basement membrane proteins from the 
Engelbreth-Holm-Swarm (EHS) tumor that forms a 3D gel at 37°C and support 
cell morphogenesis, differentiation, and tumor growth (241). In vivo, endothelial 
cells are in contact on their basal surface with a thin basal membrane matrix. 
This matrix forms a continuous sleeve around the endothelial cells, and 
maintains the tube-like structures of the blood vessels (242, 243). The biological 
function of this basement membrane matrix was demonstrated when Kubota et 
al. plated endothelial cells on a reconstituted basement membrane matrix and 
found that they rapidly attached, aligned, and formed capillary-like tubules (244). 
The process is rapid, taking 2-3 hr for immortalized endothelial cells, and 6-20 hr 
for primary endothelial cells to complete the process. The vessels that are 
formed contain a lumen and tight cell-cell contacts. The cells are polarized with 
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the nuclei located towards the basement membrane matrix. Furthermore, the 
capillary-like structures take up acetylated low-density lipoprotein (LDL), which is 
a marker of differentiation for these cells. Such LDL uptake is not observed when 
these cells are cultured in monolayer on either plastic or collagen I substrates 
(244). 
The normal basement membrane contains many proteins that vary in both 
amount and type, depending on the tissue of origin and function of the vessel. 
The major components of the vascular basement membrane are laminins 8 and 
10, collagen IV, and nidogens/entactins 1 and 2. Many isoforms of these and 
other molecules are also found in different basement membrane matrices and 
further contribute to complexity. For example, there are six isoforms of collagen 
IV chains resulting in 56 possible combinations of trimers. Collagens VIII, XV, 
and XVIII, heparan sulfate proteoglycans, growth factors (FGF, TGF, PDGF, and 
VEGF), matrix metalloproteinase proenzymes (MMPs), 
BM40/SPARC/osteonectin, fibulins 1 and 2, thrombospondins 1 and 2, and 
fibronectin, are also reported in basement membrane matrices (245-247). 
The complexity and dynamic nature of the endothelial basement membrane 
contributes to its various functions. Collagen IV is a scaffolding protein involved 
in the basement membrane’s structural integrity and promotes cell adhesion and 
migration (242). Heparan sulfate proteoglycans link collagen and laminin 
networks, bind soluble components such as growth factors, and regulate the 
filtration activity of the basement membrane matrix (248). Laminins are 
considered the major biologically active components of the basement membrane, 
in part because they are the largest proteins in the basement membrane at over 
one million Daltons (249, 250). Laminins organize and establish the basement 
membrane matrix and promote endothelial cell adhesion, migration, and 
differentiation. Fibulins bind to many matrix molecules to promote basement 
membrane stability, adhesion and migration (251). 
Vascular tube formation on basement membrane has been widely used as 
screen for angiogenic and anti-angiogenic factors (252, 253). As a first screen 
assay, it has many advantages. It is rapid, quantitative, and can be done in high 
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throughput mode to screen large numbers of chemicals. Reduced growth factor-
basement membrane can be prepared. This material is advantageous for testing 
factors that promote angiogenesis because tube formation in absence of added 
angiogenic factors is greatly reduced over complete basement membrane matrix. 
Moreover, organization of endothelial cells on basement membrane 
encompasses all steps in the angiogenic process: adhesion, migration, protease 
activity, alignment, and tube formation. Since the assay reflects these multiple 
events, it has many advantages over other in vitro assays, such as independent 
cell attachment, proliferation, migration, and invasion. These other assays 
measure individual events in the angiogenic process. Endothelial cell migration 
or invasion assays are useful but more difficult to perform, and, for a first screen, 
it is possible that they would not measure the activity of a factor that may 
regulate only tube formation (254, 255). Other in vitro tube forming assays, such 
as tube formation on collagen I gels, are not in wide use because they require 
longer time periods, their cells do not all form tubes (making quantification 
difficult), and the tubes might not be properly polarized (256). 
The formation of endothelial tubules on basement membrane allows investigators 
not only to study factors that regulate this process, but also to define genes and 
signaling pathways that cannot be studied easily in vivo (101, 257). In this way, it 
serves as a model for the molecular dissection of tube formation. Because it is 
functional for multiple uses, this will continue to be widely used to study the 
angiogenesis both in physiologic that pathological processes. 
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AIMS 
 
Exosomes are small membrane vesicles of endocytic origin secreted by both 
normal and tumor cells (108). An increasing body of evidence indicates that they 
play a pivotal role in cell-to-cell communication. Indeed, they may directly 
stimulate target cells by receptor-mediated interaction or may transfer bioactive 
molecules including membrane receptors, proteins, mRNAs, and miRNAs (106). 
Recent studies have shown that exosomes may also be enriched in angiogenic 
proteins (164). 
Angiogenesis has a major role in growth, dissemination and metastasis in solid 
tumors (258-260). More recently, angiogenesis has been described as important 
in the behavior of hematopoietic tumors, including CML progression. There is a 
significant increase in the number of vessels in the bone marrow of patients with 
CML (261). Moreover, the detection of angiogenic factor receptors in leukemia 
cell lines (262) suggests that angiogenic factors may have a direct effect on 
marrow vascularity as well as on leukemic cells. 
Imatinib mesylate, a specific inhibitor of BCR/ABL protein tyrosin kinase activity, 
has been recently developed as the treatment of choice for CML (96). Treatment 
with imatinib decreases the VEGF plasma concentration in patients with CML 
(263). And, imatinib treatment in vivo of nude mice xenografted with K562 CML 
cells resulted in a significant reduction in tumor size and microvessel density 
compared with untreated tumors (264). In this context, we hypothesized that 
during CML progression there is a close interaction between exosome secretion, 
angiogenesis and tumor cell behaviour. 
Hypothesis: Exosomes released by K562 CML cells drive pro-angiogenic 
endothelial cells behaviour. 
Specific aims: (A) to evaluate the effect of exosomes released by K562 CML 
cells in stimulating human vascular endothelial cells (HUVECs) differentiation into 
tubular structures; (B) to dissect K562 CML exosome internalization, intracellular 
exosome movement, and cell-cell communication during HUVEC tube formation; 
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(C) to evaluate the role of small molecule BCR/ABL kinase inhibitors on exosome 
effects on HUVEC differentiation. 
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MATERIALS AND METHODS 
 
Cell cultures and reagents 
 
The human erythroid leukemia cell line K562 was provided by Dr R. Childs 
(Hematology Branch, NHLBI/NIH, Bethesda, MD) and was cultured in DMEM 
(Gemini Bio-Products, Sacramento, CA) supplemented with 10% FBS, 2mM L-
glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin. Human umbilical vein 
endothelial cells (HUVEC) were purchased from Invitrogen (Carlsbad, CA) and 
were cultured in Medium 200 supplemented with 2% low serum growth 
supplement (LSGS), 100 IU/ml penicillin and 100 µg/ml streptomycin. Imatinib 
mesylate (IM) was provided by Dr. R. Bertieri (Novartis, Milan, Italy) and was 
prepared as a 10 mM stock solution in sterile phosphate buffered saline (PBS) 
and stored at -20°C until use. Dasatinib (Selleck Chemicals LLC, Houston, TX) 
was prepared as a 50 mg/ml stock solution in dimethyl sulfoxide (DMSO) and 
stored at 4°C until use. 
 
Isolation of exosomes  
 
Exosome-free medium (EFM) was obtained by ultracentrifugation at 100,000 x g 
of DMEM containing 20% FBS for 16 hr at 4°C, to remove bovine microvescicles. 
Ultracentrifuged medium was then diluted 1:1 with DMEM without FBS to obtain 
a final concentration of 10% FBS. K562 cells were cultured in EFM and the 
conditioned medium (CM) from 12 x 107 cells (160 ml) was collected after 24 h 
for exosome purification. Exosomes were isolated by differential centrifugation as 
previously described (175) with the following modifications (Fig 1M). Briefly, CM 
was centrifuged progressively at 300 x g for 10 min, 2000 x g for 10 min, then 
filtered through a 0.22 µm filter sterilization device (Steriflip; Millipore, Billerica, 
MA) to eliminate cell debris and larger vesicles. The CM was then centrifuged at 
100,000 x g for 2 h using a Type 70 Ti rotor in a Optima L-90K ultracentrifuge 
(Beckman Coulter, Brea, CA). All the centrifugation steps were performed at 4°C. 
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The exosome pellet was washed in PBS to eliminate contaminating proteins, and 
ultracentrifuged again under the same conditions. The final pellet was 
resuspended in PBS and exosome protein content measured by BCA assay 
(Pierce, Rockford, IL). 
 
 
 
Figure 15: Flow chart for the exosome isolation procedure. The speed and 
length of each centrifugation are indicated to the right of the arrows. After the first 
two centrifugations, pellets are discarded and supernatant kept for the next step. 
After the two 100,000 X g centrifugations, pellets (consisting of exosomes) are 
kept and supernatant discarded. 
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Electron microscopy 
  
An aliquot of exosome suspension was loaded into a carbon-coated electron 
microscopy (EM) grid. The sample was fixed with 2% glutaraldehyde and 2% 
paraformaldehyde in sodium cacodylate buffer for 2 min. After two washes in 
distilled H2O, the sample was overlaid with 2% methylamine tungstate for 45 
seconds and allowed to air dry. EM samples were observed in a Zeiss 
transmission electron microscopy (TEM) 912. 
 
Acetylcholinesterase activity assay 
 
A total of 40 µg of exosomes in 100 µl of PBS were resuspended in a solution of 
1.25 mM acetylthiocholine and 0.1 mM 5,5’-dithiobis(2-nitrobenzoic acid) in a 
final volume of 1 ml. Incubation was carried out in cuvettes at 37°C, and the 
change in absorbance at 405 nm was followed at different time points (0, 5, 15, 
30, 60 and 120 min). 
 
XTT cell viability assay 
 
K562 cells were seeded at 12,000/well in a final volume of 100 µl in 96-well flat-
bottom microtiter plates with increasing concentrations of IM or dasatinib. Plates 
were incubated at 37°C in a 5% CO2 incubator for the indicated time periods. At 
the end of incubation, 100 µl of XTT solution mix (sodium 3’-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic 
acid hydrate) (Roche Applied Science, Indianapolis, IN) was added to each well, 
and plates were incubated at 37°C for 4 h. Absorbance was measured at 450 nm 
against a reference wavelength at 650 nm using a microplate ELISA reader. 
Calculation of XTT viability was done using the following formula: 
 
(A450 – A650) test cells         x 100 = percent viable 
(A450 – A650) control cells 
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Protein extraction 
 
K562 cells were washed three times in PBS by centrifugation at 200 x g for 5 min 
at 4°C. The pellet was lysed in modified RIPA buffer (50 mM Tris pH 7.5, 150 mM 
NaCl, 4 mM EDTA, 10 mM Na pyrophosphate, 2 mM Na2VO4, 1% NP-40, 0.1% 
Na-deoxycholate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF) on ice for 
1.5 h. The cell lysates were then centrifuged at 14,000 x g at 4°C for 15 min to 
remove DNA and particulate cell debris. The supernatant was recovered and 
stored at -80°C; before storage, protein concentration was determined using the 
BCA assay. 
 
Protein quantification (BCA assay) 
 
Protein quantification was performed using a colorimetric BCA protein assay kit 
(Pierce, Rockford, IL). In a 96-well flat-bottom microtiter plate, 10 µl of sample 
diluted 1:10 were added to 200 µl of working reagent. To prepare the working 
reagent, 50 parts of reagent A (containing sodium bicinchoninate, sodium 
carbonate, sodium bicarbonate and sodium tartrate in 0.1M sodium hydroxide) 
were mixed to 1 part of reagent B (containing 4% cupric sulfate in distilled water). 
Absorbance was measured at 562 nm and protein concentration calculated using 
a standard curve of bovine serum albumin (BSA). Standard curves were routinely 
linear with linear regression coefficients of 0.99X. Final concentration was 
calculated from the linear regression equation. 
 
Western blot analysis 
 
Cell lysates or exosomes were heated at 95°C in SDS sample buffer (0.125 M 
Tris-HCl pH 6.8, 4% SDS, 100 mM DTT, 0.004% bromophenol blue, 20% 
glycerol) for 5 min. Then 20 µg aliquots of proteins were loaded onto tris-glycine 
SDS-PAGE gels. Electrophoresis gels were subjected to 125V for approximately 
90 min in running buffer (25 mM Tris, 0.2 M glycine, 0.1% SDS). Separated 
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proteins were then transferred to nitrocellulose membranes in transfer buffer (25 
mM Tris, 0.2 M glycine, 20% methanol) at 170 mA for about 1 hr. The 
membranes were blocked for 1 h in PBS-0.1% Tween 20 containing 5% non fat 
dry milk, and then incubated over night at 4°C with primary antibody in PBS-0.1% 
Tween 20 containing 5% BSA. Specific antibodies used included: anti-CD63 
(Abcam, Cambridge, MA), and anti-CD81 and anti-Tsg101 (Santa Cruz 
Biotechnology, Santa Cruz, CA). After three washes, membranes were incubated 
at room temperature with horseradish peroxidase-linked goat anti-mouse 
secondary antibody for 1 hr (Santa Cruz Biotechnology, Santa Cruz, CA).  Bands 
were detected via enhanced chemiluminescence (Super Signal, Pierce, 
Rockford, IL) with Kodak film. Representative Western blot images are from 
triplicate experiments. 
 
Endothelial tube formation assay 
 
Subconfluent HUVECs were harvested and resuspended in limiting medium 
(Medium 200 with 0.2% LSGS) containing the indicated concentration of 
exosomes. This suspension was seeded (70,000 cells per well) on a growth 
factor reduced Matrigel- coated 24 well plate (BD Bioscience, San Jose, CA) and 
incubated for 6h at 37°C. As described in some experiments HUVECs were 
incubated with 10 µg/ml of exosomes and treated with increasing concentrations 
of imatinib (0.1, 1, 5 and 10 µM), or dasatinib (0.1, 1, 10 and 100 nM), or vehicle 
(DMSO) for 6h. Tube formation was examined under an inverted microscope and 
photographed using a 40X objective. Total tube length was measured using the 
NIS elements program (Nikon Instruments Inc., Melville, NY). Results are the 
mean of triplicate experiments 
 
Labeling of exosomes 
 
Exosomes from K562 cells were labeled using PKH26 (red) or PKH67 (green), 
membrane-binding fluourescence labels (Sigma-Aldrich, Allentown, PA). 
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Exosomes were resuspended in 500 µl of Diluent C from the kit, then mixed 
rapidly with 500 µl of freshly prepared PKH solution (final concentration during 
labeling step: 2 x 10-6 M) and incubated for exactly 3 min to ensure 
homogeneous staining. The labeling step was stopped by addition of an equal 
volume of FBS for 1 min, followed by an equal volume of complete DMEM 
medium. Stained exosomes were washed three times in PBS and 
ultracentrifuged. The collected exosomes were resuspended in 200 µl of PBS, 
and concentrated to 100 µl using an Amicon Ultra Concentrator with a 50kDa 
MW cut-off. The flow-through (100 µl) was used as control to determine the 
effects of free fluorescent dye present in the PBS used for suspension of the 
exosomes. 
 
Internalization of PKH-labeled exosomes and immunofluorescence 
 
HUVECs seeded on Matrigel-coated chamber slides were incubated at 37°C with 
labeled exosomes at a concentration of 1 µg exosomes per 10,000 cells. Uptake 
of exosomes was stopped by aspiration of medium and gentle washing three 
times with PBS, followed by fixation in 4% paraformaldehyde for 10 min at room 
temperature (RT). The cells were permeabilized for 5 min with 0.1% Triton-X 100 
in PBS, blocked with 5% BSA in PBS and incubated with phalloidin AlexaFluor 
488 (Invitrogen, Carlsbad, CA) for 20 min. Some slides were incubated with 
mouse monoclonal anti-α-tubulin (Sigma-Aldrich, Allentown, PA) overnight after 
which they were exposed for 1h at RT to secondary anti-mouse AlexaFluor 488 
(Invitrogen, Carlsbad, CA) followed by incubation with phalloidin AlexaFluor 647 
(Invitrogen, Carlsbad, CA) for 20 min. Chamber slides were mounted using DAPI 
Vectashield medium (Vector Labs, Burlingame, CA). Confocal images were 
sequentially acquired with Zeiss AIM software on a Zeiss LSM 510 Confocal 
system (Carl Zeiss Inc, Thornwood, NY) with a Zeiss Axiovert 100M inverted 
microscope and UV laser tuned to 364 nm, a 25 mW Argon visible laser tuned to 
488 nm, and a 1 mW HeNe laser tuned to 543 nm. A 40X Plan-Neofluar 1.3 NA 
oil immersion objective was used. Emission signals after sequential excitation of 
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DAPI, AlexaFluor 488, and AlexaFluor 568 by the 364 nm, 488 nm, or 543 nm 
laser lines were collected with a BP 385-470 filter, BP 505-530 or LP 560 filter 
respectively, using individual photomultipliers. Z-stacks consisted of 16 to 54 
slices at 0.5 or 1 µm intervals and these stacks were used with Bitplane’s Imaris 
software (v6.0; Zurich, Switzerland) for surface rendering. In some cases, a 
cutting plane was used to expose internal surface or outer surface were made 
semi-transparent. 
 
Exosome transfer assay 
 
Two labeled populations of HUVECs were generated after incubation of the cells 
in standard culture monolayer for 3 h with PKH26- or PKH67-labeled exosomes. 
Following incubation, cells were harvested; the two labeled cell populations were 
mixed 1:1 and the cells seeded on Matrigel-coated chamber slides for a 4 h 
incubation. After the incubation, cells were fixed, mounted and examined by 
confocal microscopy as described above for the presence of double stained cells. 
 
Src and FAK activation assessment 
 
Subconfluent HUVECs were harvested and resuspended in basal medium 
containing a concentration of 10 µg/ml of exosomes. This suspension was 
seeded (70,000 cells per well) on a growth factor reduced Matrigel- coated slide 
chamber. The cells were allowed to adhere for 30 min in presence of dasatinib 
(10 nM), imatinib (1 µM), or vehicle (DMSO). After the incubation cells were 
washed in PBS and immunofluorescence was performed as described above. 
Cells were incubated with the anti-phospho-Src (Tyr416; Cell Signaling 
Technology, Beverly, MA), and anti-phospho-FAK (Tyr861; Millipore, Billerica, 
MA) over night, after which they were exposed for 1h at RT to secondary anti-
mouse AlexaFluor 568 (Invitrogen, Carlsbad, CA). 
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Statistical analysis 
 
Data are expressed as mean±SEM of at least triplicate experiments. Statistical 
analyses were performed using the unpaired two-tailed Student’s t-test. 
Differences were considered statistically significant at P < 0.05. 
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RESULTS 
 
Exosome isolation protocol optimization 
 
Exosomes are small vesicles that originate from the inward budding of the 
endosomal membrane forming MVBs. They are then released in the extracellular 
milieu by fusion of MVBs with the plasma membrane (108). Exosomes have 
been successfully isolated from cell supernatant and body fluids. The original 
protocol used for exosome isolation involved several centrifugation and 
ultracentrifugation steps (175). Over the years, several modifications to this 
protocol have been made. However, optimization of the exosome isolation 
protocol was still required to obtain clean exosome preparations. 
Most of the cells need the presence of serum to grow in vitro. Serum generally 
used for cell culture is unprocessed except for heat inactivation; thus, it would be 
expected to be contaminated by exosomes of the host from which the serum is 
drawn. These exosomes, if not depleted from serum, will contaminate the 
conditioned medium and therefore bias the experiment. To eliminate serum 
exosomes, serum or medium containing 20% serum was ultracentrifuged for 
different times, and the concentration of contaminating protein, representative of 
contaminating exosomes, was measured by BCA (Figure 16A). It was found that 
ultracentrifugation for 16 h yielded pellets containing more contaminating protein 
than ultracentrifugation for 1 h, the time recommended for exosome isolation 
(121). Moreover, it was observed that dilution of serum in medium increased the 
amount of contaminating material spun down compared to the undiluted serum. It 
was concluded that ultracentrifugation of medium containing 20% serum for 16 h 
is the optimal way to obtain an exosome-producing medium clear from 
contaminating exosomes. 
Cell culture supernatant obtained after incubation of cells in exosome-producing 
(precleared) serum-containing medium can contain several types of vesicles. 
Therefore, it was important to ensure that the isolated vesicles were exosomes.  
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Figure 16. Elimination of contaminating exosomes from serum and evaluation of 
exosome AChE activity. A) Fetal bovine serum (FBS) or medium supplemented with 
20% FBS were ultracentrifuged at 100,000 x g, 4°C at different times and total amount of 
protein in the pellet was quantified by BCA. B) Exosomes isolated from K562 cells were 
analyzed for the AChE activity. FBS was used as control. C) Analysis of AChE activity in 
serums from different companies. 
 
Intermediate ultracentrifugation steps were replaced with filtration using a 0.22 
µm filter. This filtration step allowed to eliminate larger vesicles and enrich the 
preparation for exosomes. There are different methods to characterize and 
assess the purity of the isolated exosomes. Since exosomes are reported be 
enriched in acetylcholinesterase (AChE), one such method applies quantification 
of AChE activity using a spectrophotometric assay. An exosome preparation was 
analyzed by AChE assay, using as control the serum (Figure 16B). It was found 
that exosomes displayed a high AChE activity. However, the serum also 
displayed AChE activity. To determine if the AChE activity generally is found in 
commercially available serum, AChE activity in sera from an additional company 
was tested (Figure 16C). AChE activity was found in both sera tested, but the 
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FBS 1 had very high activity compared to the FBS 2, in which the activity was 
low. These experiments allowed to verify that while the AChE assay is described 
as a good method to characterize vesicles as exosomes, it was not specific and 
could be misleading. Hence, other methods of validation are needed to be sure 
that the preparation consists of exosomes. 
 
Characterization of K562 exosomes 
 
The results of the K562 exosome purification procedure were further validated in 
two ways: electron microscopy and selective protein expression. Figure 17A 
shows an example of exosome preparation analyzed by transmission electron 
microscopy. The arrow points to the characteristic cup-shaped morphology and 
the sizing bar indicates that the vesicles in the preparation have the characteristic 
diameter range of 40 to 100nm.  
 
 
Figure 17: Characterization of exosomes released by K562 cells. A) Exosomes 
isolated from medium conditioned by K562 cells analyzed by transmission electron 
microscopy. Arrow: cup-shaped exosome. Scale bar 150 nm. B) Exosome 
characterization by immunoblot. Equal amounts of total exosomal proteins (Exo) and 
K562 cell lysate (CL) were analyzed for the expression of CD63, CD81, and Tsg101. 
 
Next, the exosome pellet obtained after ultracentrifugation of the CML cell 
supernatant was analyzed by Western blot. CD63, CD81 and Tsg101 are known 
exosomal markers (121). Figure 17B shows the expression of these markers in 
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exosomes purified from K562 cells compared to equal amount of the K562 cell 
lysate. CD63 and CD81 are absent in lysate but found in abundance in the 
exosomal preparation.  Tsg101 appeared equally present in both, suggesting 
enrichment in the exosomal compartment. It is therefore possible to conclude 
that the K562 cells release true exosomal vesicles into their conditioned medium. 
 
Exosomes induce vascular tube formation in vitro 
 
Angiogenesis has been demonstrated in the bone marrow of CML patients (261). 
We hypothesized that exosomes from K562 CML cells would induce tubular 
differentiation of HUVECs in culture. The effect of exosomes was examined by 
an endothelial tube formation assay. HUVECs were plated on Matrigel in low 
growth factor medium (see Materials and Methods) in presence of increasing 
concentrations of K562 exosomes and incubated for 6 hours to allow tubes to 
form.  
 
 
Figure 18: Dose-dependent stimulation of vascular tube formation by K562 
exosomes. A) Exosomes promote tube formation by HUVECs on Matrigel B) 
Quantitative analysis of the total tube length (* p < 0.01 vs control). 
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Compared to the control, exosomes induced tube formation in a dose-dependent 
manner (Figure 18A). Addition of 5 µg/ml exosomes stimulated a morphologic 
change in HUVECs without significantly increasing the tube network formation as 
measured by cumulative tube length (Figure 18B). Increasing the dose to 10 
µg/ml resulted in almost 100% increase in tube formation with respect to 
endothelial cells grown in low serum control medium. Quantitative analysis 
showed that exosomes induced a significant (P<0.01) increase in the total tube 
length at the dose of 10 µg/ml (Figure 18B). HUVECs exposed to a higher single 
dose of exosomes showed a reduced cumulative tube length and poor cellular 
organization compared to the 10 µg/ml dose. 
 
 
Figure 19. Tube formation induction related to the timing of exosome addition. 
Quantitative analysis of the total tube length in HUVECs plated on Matrigel and treated 
with increasing doses of exosomes given in sequential 10 µg/ml doses (A), or treated 
with a 10 µg/ml dose with increased delay of exosome addition (B). 
 
To determine whether reduction of tube formation was due to a toxic effect of the 
exosome dose, HUVECs were exposed to 2 or 3 repetitive additions of 10 µg/ml 
doses of exosomes over a 3-4 hour period. As shown in Figure 19A, exposure to 
20 µg/ml exosomes given in two 10 µg/ml doses (0 and 3 h) induced greater 
formation of tubes compared to a single 10 µg/ml dose given at time 0 h. Three 
additions of 10 µg/ml of exosomes (0, 2 and 4 h), a total of 30 µg/ml, further 
increased tube formation compared to the one or two time addition. This would 
suggest that the toxicity of 20 µg/ml dose (Figure 19B) might be due to the bolus 
effect rather than the total exposure over time. Next, it was examined whether 
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the timing of exosome addition was important for tubular differentiation. As 
previously demonstrated, addition of 10 µg/ml of exosomes at the initiation of 
tube formation induced an almost two-fold increase in cumulative tube length 
(Figure 19, red bars). The orange bar in Figure 19B shows that delaying 
exosome addition by 1 h resulted in an approximately 50% loss of net tube 
formation. Greater loss in exosome response was observed with increased delay 
of introduction of exosomes (Figure 19 brown bar). Stimulation was completely 
lost by the addition of exosomes after 3 h (Figure 19 purple bar). This suggest 
that there is an optimal exosome quantity for stimulation of tubular differentiation 
and the response was also time-dependent, with delay resulting in a reduced or 
lost response. 
 
Exosomes are internalized by endothelial cells during tube formation 
 
We posited that exosomes must be internalized in order to effect their function. 
Exosome internalization and intracellular localization during tube formation were 
examined in HUVECs on Matrigel. Exosomes were stained with PKH26, a 
membrane fluorescent dye. HUVECs were then incubated with PKH26-labeled 
exosomes and uptake was evaluated at different time points (Figure 20). At early 
stages of tube formation, cells were spread on Matrigel and exosome uptake was 
detectable (Figure 20A). Localization was mainly perinuclear (Figure 20A, 
arrows) suggesting that internalization occurs following the endocytic pathway as 
previous described for cells growing in monolayer. Cells start organizing into 
tubes after 1 h, and exosome localization remains chiefly perinuclear during this 
early time of differentiation (Figure 20B, arrows). Tube formation is not completed 
after 2 h but exosome localization starts to change. Predominant localization 
remains perinuclear, especially in cells that are not differentiating. However, 
exosomes begin to move to the cell periphery and into the arm of extending cells 
(Figure 20C, arrow). Tubes are mostly formed by 4h and it was observed an 
increase in the total amount of exosomes internalized (Figure 20D). Furthermore, 
exosomes diffused more broadly within the cytoplasm and a large quantity of 
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exosomes was localized in the cell periphery. In particular, exosomes were found 
in nanotubular structures connecting neighbor cells (Figure 20D, arrow). No red 
fluorescence was observed in the control cells (see “Labeling of exosomes” in 
Materials and Metods) (Figure 20 E). Thus, exosome uptake increases over time 
and their localization into the nanotubes suggests an involvement of these 
structures in functional exosome movement. 
 
 
 
 
 
Figure 20: Time dependent uptake and localization of exosomes in HUVEC cells 
during differentiation. At the time of plating on Matrigel exosomes labeled with PKH26 
(red) were added to the HUVEC cells and incubated for 30 min (A), 1 h (B), 2 h (C), and 
4 h (D). As control a suspension of PKH26-labeled exosomes were filtered (as described 
in Materials and Methods) and the flowthrough was incubated with the HUVECs (E). 
After the incubation the cells were fixed and stained for the actin cytoskeleton (green), 
and the nuclei (DAPI). Arrows indicate exosome localization at the different time points 
of tube formation. 
 
 
 
Results  
 
 54 
Exosomes localize inside nanotubes 
 
To examine nanotube structure and exosome localization inside these structures, 
HUVECs were incubatedwith PKH26-labeled exosomes on Matrigel to allow 
nanotube formation. Then HUVECs were then fixed and stained for actin and α-
tubulin. As shown in Figure 21 nanotubes connecting HUVECs contained both 
microtubules and actin (Figure 21B and C). Immunostaining of nanotubes and 
confocal analysis confirmed exosome presence within cell-to-cell connections 
(Figure 21A). 
 
 
Figure 21. Exosomes localize inside nanotube structures. HUVEC cells incubated 
with PKH26-labeled exosomes (A) on Matrigel reorganized and sent out pseudopods 
that extended into nanotubes containing both F-actin (B) and microtubules (C). Nuclei 
were stained with DAPI (D). Merged image (E) shows the localization of exosomes at 
level of the nanotube.  
 
 
Exosome localization inside the nanotubes was further confirmed through a 3D 
reconstruction of the confocal images by surface rendering using the Imaris 
software (Figure 22). A projection of the Z-plans showed in Figure 21E was used 
to create a 3D volume rendered image. Contrast, brightness and opacity of the 
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image were adjusted to optimize the volume rendering. Then, for each channel a 
surface was created, setting the threshold in order to reduce the background 
fluorescence. 
 
 
Figure 22. Three-dimensional reconstruction of nanotubes. A) Surface rendering of 
two HUVEC cells carrying exosomes (red) connected by nanotube. HUVECs were 
stained for actin (pink), tubulin (green) and nuclei (blue). B) Semi-transparency of the 
pink and the green (B), and sections of the nanotube (C-H) show that exosome localize 
inside the nanotube. 
 
This procedure allowed to obtain a 3D image of the nanotubes, shown in Figure 
22A. Semi-transparency of actin and tubulin, and sections of the 3D image 
confirmed that exosomes were transported inside the nanutubes (Figure 22B-H). 
This approach allowed examination of the actin and tubulin network within the 
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nanotube structure. They were found in a loose network without clear 
organization (Fiugure 22E and H). 
 
Exosome are transferred cell-to-cell by nanotube formation 
 
To examine the possibility of cell-to-cell transfer of exosomes, it was examined 
exosome localization during tube formation using a mixed cell suspension 
composed of two different populations of HUVECs.  
 
 
Figure 23. Exosomes are transferred cell to cell. HUVECs carrying PKH26-stained 
exosomes (A, red) were mixed with HUVECs carrying PKH67-stained exosomes (B, 
green) and plated on Matrigel for 4 h. After the incubation, cells were fixed and DAPI 
stained for nucleai (C). Tube forming cells show the presence of both green and red 
exosomes inside the same cell (arrows) 
 
The first population of cells was preincubated with PKH26-stained red fluorescent 
exosomes, while the second population was preincubated with PKH67-stained, 
green fluorescent, exosomes. They were mixed and plated on Matrigel to form 
tubes. Four hours later, the tubular network showed HUVECs containing both red 
and green exosomes (arrows, Figure 23). A subset of cells, those involved in the 
tubular network, contained colocalized red and green exosomes (Figure 24E). 
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The arrows in Figure 24 indicate cells containing red exosomes colocalized 
internally with green exosomes. These data suggest a cell-cell transfer and that 
the green and red exosomes colocalize to the same subcellular organelle. 
 
 
Figure 24. Colocalization of exosomes after cell-to-cell transfer. The tube network 
formed by HUVECs positive for both PKH26 (A) exosomes and PKH67 (B) exosomes 
displayed cells in which some of the red exosomes colocalized with the green exosomes 
(arrows). 
 
To finally demonstrate exosome transfer through nanotubes and characterize the 
exosome movement, time-lapse video microscopy was performed. This enabled 
to track exosome movement over time. It was observed that exosomes in the 
perinuclear area showed mostly a vibratory movement; whereas, those inside the 
nanotubes moved straight from one cell to the other. It was possible also to 
detect both unidirectional movement in some nanotubes and bidirectional 
movement in other (Figure 25A-D). Overall, these experiments demonstrate that 
HUVECs can internalize exosomes, and transfer them to neighboring cells 
through extended nanotube structures. 
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Figure 25. Exosomes move along nanotubes. HUVECs were incubated with PKH26-
labelled exosomes and analyzed by fluorescent time lapse videomicroscopy. A and C) 
Brightfield view of HUVECs carrying exosomes (arrows) connected by nanotubes. B and 
D) Selected frames of a video sequence showing unidirectional (B) or bidirectional (D) 
transfer of PKH26 exosomes (dotted arrows indicate direction of movement). 
 
 
Imatinib affect CML tumor cells but not tumor microenvironment 
 
Imatinib mesylate is a selective inhibitor of ABL protein tyrosine kinase activity, 
with inhibitory activity against the BCR/ABL proto-oncogene (265, 266). It has 
been shown recently that imatinib-treated CML patients have a reduced plasma 
VEGF concentration (263). This finding suggests that imatinib may have a 
potential role in modulation of bone marrow angiogenesis. To determine whether 
imatinib is able to reduce exosome release and pro-angiogenic effects, K562 
CML cells were treated with non-toxic dose of imatinib and exosomes isolated 
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from these cells evaluated for angiogenic effects. The XTT cell proliferation 
assay was performed on K562 cells using different concentrations of imatinib in 
order to establish the dose that doesn’t have toxic effects. After 24 h of imatinib 
treatment, K562 cells proliferation was reduced of 20% (Figure 26A). A dramatic 
decrease of the proliferation was seen after 48 h with a 66% reduction in cell 
proliferation at the dose of 1 µM imatinib (Figure 26B). 
Next, exosomes were isolated from K562 with or without 0.125 µM of imatinib 
treatment for 24 h. This concentration of imatinib was chosen because had a little 
effect on proliferation of K562, with a cells viability >99% calculated by trypan 
blue exclusion test, as well as to reduce the possibility of presence of apoptotic 
bodies in the conditioned medium of K562. The preliminary data show that K562 
cells still release exosomes when treated with 0.125 µM imatinib since we were 
able to recover vesicles expressing the exosomal markers CD81 and Tsg101 
(Figure 26C). The quantity of released exosomes was determined by 
measurement of total amount of protein in the exosome preparation pellet. The 
amount of secreted exosomes was reduced by 58% in the imatinib-treated cells. 
The next question was to evaluate the functional ability of exosomes released by 
imatinib-treated cells (IM-exosomes). HUVECs were plated on Matrigel in low 
growth factor conditions, as in Figure 18, in the presence of K562 IM-exosomes 
and tube formation was measured after 6 h of incubation. As shown in figure 26E 
IM-exosomes induced formation of tubular structure by HUVECs, with a 2 fold of 
increase in the total tube length at the dose of 10 µg/ml. These results suggest 
that imatinib regulates exosome secretion process but does not change exosome 
angiogenic activity. 
Next it was evaluated the effect of imatinib directly on HUVEC uptake and 
response to exosomes from untreated K562 cells. First, the effect of imatinib on 
HUVECs viability was evaluated. An XTT cell proliferation assay was performed 
treating HUVECs with increasing concentrations of imatinib (range: 0.1-10 µM) 
for 24 and 48 h (Figure 27). 
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Figure 26. Imatinib affects exosome release but not exosome function. XTT cell 
proliferation assay of K562 treated for (A) 24 h and (B) 48 h, with increasing 
concentrations of imatinib (0.125-1 µM). C) IM treatment does not alter characteristic 
exosomal protein expression. Equal amount of exosome proteins and IM-treated K562 
cell lysate (CL) were analyzed for exosomal markers CD81 and Tsg101. D) Total 
amount of proteins in the exosomal pellet purified from K562 control cells and K562 
treated with the non-toxic dose of imatinib 0.125 µM (IM exo) for 24 h (*p = 0.0018). E) 
Quantitative analysis of cumulative HUVEC tube length shows that IM exosomes 
promote tube formation (**p < 0.05).  
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No toxic effects of imatinib were seen after 24 h of incubation (Figure 27A), and 
only a 20% of reduction in HUVEC proliferation was demonstrated at the highest 
tested concentration (10 µM) at 48 h (Figure 27B).  
 
Figure 27. Imatinib does not affect exosome uptake or tube formation of HUVECs 
at non-toxic concentrations. XTT cell proliferation assay of HUVECs treated with 
increasing concentrations of imatinib (0.1-10 µM) for (A) 24 h and (B) 48 h shows that 
imatinib has limited activity against HUVEC cells. C) HUVECs were incubated on 
Matrigel for 4 h with PKH26-labeled exosomes (red) and with or without 1 µM imatinib. 
After incubation cells were fixed and stained for nuclei (blue). D) Quantitative analysis of 
the total tube length in HUVECs plated on Matrigel and treated with increasing doses of 
imatinib (0.1-10 µM) and incubated with 10µg/ml of exosomes for 6 h. 
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Next, HUVECs were incubated on Matrigel with PKH26-labeled exosomes in 
presence of 1 µM imatinib, selected for its physiologic plasma concentration in 
patients. Even if there was variability in the exosome uptake from a cell to 
another, on the whole, internalization of exosomes by HUVECs was not visibly 
altered by imatinib. Finally, HUVECs were plated on Matrigel and incubated with 
10 µg/ml of exosomes in the presence of increasing concentrations of imatinib 
(0.1-10 µM), and tube formation evaluated after 6 h (Figure 27D). No reduction in 
exosome-stimulated tube formation was seen in presence of all concentrations of 
imatinib tested. Moreover, imatinib treatment alone was able to stimulate tube 
formation in a non-concentration-dependent fashion. All together these results 
suggest that imatinib modulates CML cells but not tumor microenvironment. 
 
Dasatinib regulates both CML tumor cells and tumor microenvironment 
 
Dasatinib is a multikinase inhibitor, developed against mutant BCR/ABL and 
found to have substantial activity against the SRC family kinases, that is now 
used for the treatment of imatinib-resistant CML (91). To study the effects of 
dasatinib on exosome release and function, exosomes isolated from dasatinib-
treated K562 cells were quantified and their angiogenic effects on HUVECs 
evaluated in vitro. A dose-finding assay was done to determine the non-toxic 
dose for subsequent use. Dasatinib induced a 20% decrease in cell proliferation 
of K562 cells at the concentrations 1 and 5 nM after 24 h of treatment (Figure 
28A). Treatment with dasatinib for 48 h more substantially reduced cell 
proliferation with a 69% decrease of vitality (Figure 28B). Exosome were isolated 
from K562 cells treated with the relatively non-toxic concentration of 0.1 nM 
dasatinib, and exosome identity was confirmed by immunoblot for the exosomal 
markers CD81 and Tsg101 (Figure 28D). Isolation of exosomes from K562 cells 
teated with 0.1 nM dasatinib yielded a 56% of reduction in exosome release 
compared to the untreated cells (Figure 28C). The angiogenic potential of 
exosomes isolated from dasatinib-treated K562 cells was tested next. HUVECs 
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were plated on Matrigel and incubated with 10 µg/ml of dasatinib-K562 
exosomes. As shown in Figure 28E, dasatinib exosomes were still able to induce 
tubular differentiation with an increase of 2 fold in the total tube length. 
 
Figure 28. Dasatinib affect exosome release but not exosome function. XTT cell 
proliferation assay on K562 treated for (A) 24 h and (B) 48 h with increasing doses of 
dasatinib (0.1-100 nM). C) Dasatinib treatment does not alter characteristic exosomal 
protein expression. Equal amount of exosome proteins and dasatinib-treated K562 cell 
lysate (CL) were analyzed for exosomal markers CD81 and Tsg101. D) Total amount of 
proteins in the exosomal pellet purified from K562 control cells and K562 treated with the 
non-toxic dose of dasatinib 0.1 nM (dasatinib exo) for 24 h (*p = 0.01). E) Quantitative 
analysis of total tube length shows that dasatinib exosomes promote tube formation (**p 
< 0.05). 
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Figure 29. Dasatinib does not affect exosome uptake but blocks exosome-induced 
tube formation by HUVECs. A) XTT cell proliferation assay on HUVECs treated with 
increasing doses of dasatinib (0.1-100 nM) for 24 h and (B) 48 h shows that dasatinib 
does not have a toxic effect. C) HUVECs were incubated on Matrigel for 4 h with 
PKH26-labeled exosomes (red) and treated or not with 10 nM of dasatinib. After 
incubation cells were fixed and stained for nuclei (blue). D) Quantitative analysis of the 
total tube length in HUVECs plated on Matrigel and treated with increasing doses of 
dasatinib (0.1-100 nM) and incubated with 10µg/ml of exosomes for 6 h. 
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Again, the direct effect on HUVEC cells of the small molecule inhibitor was 
tested. To analyze the effect of dasatinib on HUVECs, XTT cell proliferation 
assay was performed on HUVECs treated with increasing concentrations of 
dasatinib (0.1-100 nM). Dasatinib caused a minimal toxic effect on HUVECs, with 
only a 20% reduction in cell proliferation after 24 h (Figure 29A) and 30% after 48 
h (Figure 29B) with the highest concentration used (100nM). The effect of 
dasatinib on HUVEC exosome uptake was then tested. HUVECs were plated on 
Matrigel in presence of 10 nM of dasatinib and incubated for 4 h with PKH26-
labeled K562 exosomes. As shown in Figure 29C, no differences in exosome 
uptake were seen in HUVECs treated with or without dasatinib. 
Finally, the effect of dasatinib on exosome-induced tube formation was analyzed. 
HUVECs were plated on Matrigel and incubated with K562 exosomes in 
presence of increasing concentrations of dasatinib (0.1-100 nM) or vehicle 
(DMSO). Low concentrations of dasatinib (0.1 and 1 nM) did not affect HUVEC 
response to exosomes (Figure 29D). On the contrary, treatment with higher 
concentrations of dasatinib (10 and 100 nM) inhibited tube formation equally and 
in dose dependent manner in HUVECs plated in low grow factor medium 
(control) and those stimulated with exosomes (Figure 29D). These results 
suggest that dasatinib is able to block both tumor cell function and, unlike 
imatinib, tumor-associated angiogenesis. This occurs, at least in part, through the 
inhibition of exosome effects. 
 
Exosomes stimulate HUVECs through the activation of Src signaling 
 
Dasatinib differs from imatinib in its ability to recognize multiple conformations of 
BCR/ABL, and also for its inhibitory activity against the Src family kinases (SFKs) 
(91). Src activity has been shown play an important role in tube formation 
stimulated by proangiogenic factors, such as VEGF and bFGF (267). 
Phoshorylation of Tyr416 in the kinase domain of Src is required for catalytic 
activity (268). The previous results suggest that HUVEC stimulation by exosomes 
could be directly correlated with the activation of the Src signaling. To assess this 
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hypothesis, HUVECs were incubated with exosomes, allowed to adhere to 
Matrigel for 30 min, and then Src activation analyzed by immunofluorescence. 
This incubation time was chosen based on the observation that the first hour of 
incubation with exosomes was important to obtain the maximum stimulatory 
response by HUVECs (Figure 19B). Figure 30 shows that HUVECs treated with 
10 µg/ml of K562 exosomes showed a higher fluorescence intensity of 
phosphorylated Src compared to the untreated control, with an increased Src 
localization at points of membrane contact (Figure 30 arrows). Dasatinib blocked 
the Src phosphorylation both in control and exosome-stimulated cells with loss of 
membrane Src staining. In contrast, imatinib treatment did not alter exosome 
effect, but resulted in a small increase in total fluorescence in control cells 
(Figure 30). 
 
 
Figure 30. Exosomes stimulate Src phosphorylation in HUVECs. Semiconfluent 
HUVECs were harvested, resuspended in basal medium, and mixed with 10 µg/ml of 
exosomes. The cell suspension was plated on Matrigel in presence of DMSO (control), 
dasatinib, or imatinib, and cells allowed to adhere for 30 min. After the incubation time, 
cells were fixed and red fluorescence labeling was performed to visualize phospho-Src. 
Nuclei were stained with DAPI (blue). 
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Next, it was investigated the effect of exosomes on focal adhesion kinase (FAK), 
a known substrate of Src. Activated Src phosphorylates FAK at the specific 
tyrosine residue Tyr861. The data indicate that exosomes induced FAK 
phosphorylation on Tyr861, and increased the number of focal adhesions (Figure 
31, arrows). FAK activation was markedly attenuated by dasatinib treatment with 
associated reduction in focal adhesions.  While there was little reduction in 
Tyr861FAK in imatininb-treated control cells, the pattern of staining was different 
in exosome-exposed cells.  Those cells had a change in the organization and 
quality of stained focal adhesions compared with vehicle-treated exosome-
exposed cells, but with limited loss of staining intensity. These findings suggest 
that Src signaling plays an important role in exosome induced tubular 
differentiation in endothelial cells. 
 
 
Figure 30. Exosomes activate Src signaling in HUVECs inducing selective 
phosphorylation of FAK. Semiconfluent HUVECs were harvested, resuspended in 
basal medium, and mixed with 10 µg/ml of exosomes. The cell suspension was plated 
on a thin layer of Matrigel in presence of DMSO (control), dasatinib, or imatinib, and cells 
allowed to adhere for 30 min. After the incubation time, cells were fixed and red 
fluorescence labeling was performed to visualize phospho-FAK (Tyr861). Nuclei were 
stained with DAPI (blue). 
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DISCUSSION 
 
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic 
stem cells that is characterized by the presence of the Philadelphia chromosome 
(3, 4). This chromosomal translocation results in the expression of the BCR/ABL 
fusion oncogene (5, 269). BCR/ABL is a constitutively activated tyrosine kinase 
that drives the pathogenesis of CML through the phosphorylation and activation 
of a broad range of downstream substrates. These are signaling proteins that 
play critical roles in cellular signal transduction and malignant transformation, and 
include RAS, PI3K and STAT5 (41, 47, 48, 62, 270). Although it is recognized 
that CML presents in three different clinical phases (1), little is known about the 
mechanism of disease progression. One hypothesis is that diverse interactions 
between leukemic cells and bone marrow microenvironment are important in the 
pathogenesis of the disease (271). 
Cells may communicate through the release of soluble factors (103), cell-to-cell 
interaction, as well as through the release of microvesicles (MVs) (106). The 
most widely studied and best known types of MVs are shedding vesicles and 
exosomes (106). Exosomes are vesicles released by cells in response to a broad 
spectrum of physiologic and pathologic conditions. They can be easily 
distinguished from the other MVs for their characteristic cup shape, their small 
size, ranging between 30 and 100 nm, and the enrichment in specific proteins, 
such as CD63, now used as exosomal markers (108). Exosomes have been 
described to play an important role in modulating tumor microenvironment, and 
promoting tumor progression (272, 273). 
Angiogenesis, the formation of new blood vessels from an existing vasculature, 
has been associated with grow and dissemination of solid tumors (274). It is now 
emerging that angiogenesis plays an important role in the pathogenesis and 
progression of hematological neoplasias (275). Increased vascularity is 
associated with a significant increase in circulation of angiogenic factors, 
including vascular endothelial growth factor (VEGF), fibroblast growth factor 
Discussion  
 
 69 
(FGF), and hepatocyte growth factor (HGF), which are specific and potent 
inducers of angiogenesis (261). Moreover, increased bone marrow vascularity is 
more prominent in CML than in other forms of leukemia (261). However, the 
extent and role of exosome release during CML progression is an area of new 
investigation. Our hypothesis was that exosomes released by CML cells could 
play a role in the stimulation of angiogenesis. 
The role of exosomes in the angiogenic process has been emerging in the last 
few years. It has been shown that exosomes from activated platelets induce 
expression of VEGF, MMP-9, interleukin-8, and HGF in lung cancer cells, and 
promote their adhesion to endothelial cells (276). Glioblastoma exosomes 
transport mRNA and proteins related to angiogenesis and promote endothelial 
cell proliferation in vitro (164). In addition, exosomes released by the D6.1A 
tetraspanin-transfected pancreatic cancer cell line induce endothelial 
tubulogenesis, a stimulation independent from the canonical angiogenic factors 
(277).  
The study described in this thesis demonstrates that the CML cell line K562 
releases exosomes into its conditioned medium. The composition of the 
exosome pellet obtained by differential ultracentrifugation has been confirmed by 
electron microscopy analysis, showing cup-shaped microvesicles ranging in size 
between 40 and 100 nm, and by the expression of the exosomal markers CD63, 
CD81, and Tsg101. It was shown here for the first time that the exosomes 
released by K562 CML cells induce tubular differentiation of HUVECs in an in 
vitro Matrigel assay. This could be the consequence of exosome uptake and 
internalization by the endothelial cells, as shown in the fluorescence tracking 
experiment using PHK-labeled exosomes. This finding suggests that exosomes 
may have an active role in CML progression through the modulation of the bone 
marrow microenvironment. 
Exosomes released from CML cells inside the bone marrow microenvironment 
may serve as an alternative mechanism for the release of angiogenic factors. 
CML patients have been shown express higher plasma levels of VEGF, bFGF, 
HGF and TNF-α compared to the normal control (261). All of these factors could 
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be potentially packed inside exosomes. In fact, bFGF and VEGF have been 
shown be released by neurons and astrocytes via shedding microvesicles (278, 
279). VEGF is also found in the cargo of tumor-derived microvesicles and is 
liberated upon disruption of the microvesicle membrane (280). It is possible that 
this form of VEGF release protects this and other factors from proteolytic 
degradation in the extracellular microenvironment. Evaluating exosome 
circulation and composition in the blood of CML patients would be the next step 
in this line of investigation. Alternatively, exosomes could be involved in the 
release of other factors that in combination with the angiogenic factors listed 
above may be responsible for overall vascularity. 
CML exosomes may stimulate angiogenesis also through the delivery of mRNA 
to the endothelial cells. It has been shown that exosomal mRNAs can be 
translated inside the recipient cell (164). This suggests that tumor-derived 
exosomes could modify the surrounding normal cells by changing their 
translational profile. Microvesicles have been also shown to transfer membrane 
receptors to recipient cells. In this case, CML exosomes could make endothelial 
cells more responsive to circulating angiogenic factors. For instance, transfer of 
tumor-derived microvesicles containing the epidermal growth factor receptor 
(EGFR) into endothelial cells was shown to result in an acquisition of 
proangiogenic activity (281). 
Next, the composition of exosomes may change during CML progression. A 
recent study has shown a change in angiogenic factor levels during the three 
clinical phases in the plasma of CML patients (282). The most significant 
increase of VEGF was found in patients in chronic phase, and VEGF levels 
decreased during the blast crisis. Instead, the highest plasma HGF 
concentrations were detected in patients in blast transformation (282). The 
discovery of a different exosome composition may add important information on 
how the CML cells change over time, and how this changes their interaction with 
the bone marrow microenvironment. 
Recent studies have been focused to better understand the fate of exosomes 
after release into the extracellular milieu. It has been proposed that an acidic 
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tumor environment can promote lysis of some of the microvesicles, making 
intravesicular proteins available for interaction with surface receptors of the target 
cells (280). On the other hand, mRNA, miRNA and some angiogenic proteins, 
such as angiogenin, require transport inside recipient cells to exert their 
biological effect (283). Recent studies report that some cell lines are able to 
internalize exosomes (164, 284); however, little is known about mechanisms 
involved in that intracellular trafficking. Our observations demonstrated that 
exosomes moved from the cell periphery, the site of uptake, to the perinuclear 
region initially. This was followed by movement back towards the membrane, 
specifically into the reorganizing pseudopodia involved in the formation of the 
tube network. Then, it was showed that exosomes were shared between 
neighboring cells. This appears to occur through the cell-cell contact of the 
tunneling nanotubes. 
Membrane or tunneling nanotubes (TNTs) are thin protrusions up to several 
micrometers long that connect cells from several cell diameters apart. They have 
been recently discovered as a new route of cell-to-cell communication. TNTs 
were originally described in cultured rat pheocromocytoma PC12 cells and 
immune cells (104). In PC12 cell cultures, TNTs were characterized as 50-200 
nm wide actin-contained stretched tubes that provide membrane continuity 
between connected cells (104). Later, formation of TNT-like structures has been 
described in other cell types. This revealed some heterogeneity regarding 
formation, structure, and functional property across cell types and even within a 
given cell type. TNT-like bridges connecting dendritic cells appear to be the most 
closely related, if not identical, to TNT described in PC12 cells (285). The 
demonstrated intercellular transfer of triggered calcium signals and of the dye 
Lucifer yellow through these structures suggests membrane continuity as 
proposed in the TNT model (285). On the contrary, TNT-like bridges between T-
cells present a similar architecture to that of PC12 TNTs and same quality of 
intercellular transfer, but they do not propagate calcium signals between T-cells. 
Furthermore, they do not permit free diffusion of fluorescent plasma membrane 
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proteins and a junctional border was detected at the ultrastructural level. Hence, 
they were classified as close-ended cellular nanotubes (286). 
Besides the emerging cell-type-specific differences of TNT-like structures, 
evidence for different classes of bridge was also provided for a given cell type as 
demonstrated for macrophage (287). These cells were found be connected by 
thin only F-actin containing nanotubes (<0.7 µm diameter) and by thicker 
microtubule-containing types of cellular connections (>0.7 µm diameter). In 
agreement with the latter type, thicker nanotubes were also found between 
prostate cancer cells (288). The diversity of the TNT-like bridges may be related 
to different transfer mechanisms. F-actin containing bridges appear to perform a 
unidirectional transfer of cellular components such as organelles (104). This 
“one-way street” principle would be in agreement with an acto-myosin-dependent 
transport assuming that the F-actin fibers inside the bridges have the same 
polarity. In contrast, a bidirectional movement of organelles along microtubules 
was observed for the thick bridges between macrophages (287). Cargo has to 
traverse the junctional border between T-cells, which may involve exocytosis and 
endocytosis. We report here that exosomes internalized by HUVECs are 
transferred to other cells through the formation of nanotubes. The nanotubes 
connecting HUVECs are composed of both F-actin and microtubule. Because of 
their composition, these structures are thick nanotubes. Software able to perform 
three-dimensional reconstruction of the nanotube structure confirmed that 
exosomes localize inside the cytoskeletal scaffold of the nanotubes. Moreover, 
HUVEC nanotubes did not present junctional borders, showing a continuous 
cytoskeletal network. Movement of the exosomes inside the nanotubes was 
further confirmed by live cell imaging, showing a bidirectional transfer of 
exosomes. 
TNTs have been reported be involved in the transfer of organelles belonging to 
the endosomal/lysosomal system (104). Bacteria have been shown surfing along 
TNT-like structures connecting macrophages (287). Moreover, transfer of 
mitochondria through myocytes nanotubes has been associated to the 
acquisition of myocyte-like phenotype in endothelial progenitor cells (289). 
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However, the first evidence of TNT-dependent functional connectivity was 
reported in myeloid cells. It was shown that calcium signals, induced in myeloid 
cells, were propagated via TNT to neighboring cells, where they elicited a 
physiological reaction (285). Evidence for the involvement of a TNT-dependent 
communication in immune defense arose from the detection of class I major 
histocompatibility complex (MHC I) in TNT between immune cells (285). This 
may point to the role of these bridges in a faster and more efficient antigen 
presentation (290). Our finding was the first to show that exosomes are 
transferred cell to cell using TNT-like structures. This transfer of exosomes could 
play an important role in propagation of exosome angiogenic information and 
potential amplification of exosome effects, adding a new step in the exosome 
trafficking after uptake. Also, this is of particular interest in the context of 
intercellular transfer of RNAs. In fact, it is known that mRNA and miRNA are 
packed inside exosomes (164). Our data, if confirmed by further experiments, 
could be the first evidence of cell-to-cell transfer of RNA through nanotubes. This 
has been demonstrated to occur through so called plasmodesmata (291), which 
are involved in direct cell-to-cell communication in plants, but not yet in other 
organisms. 
In this thesis are reported also results that represent an important first step in 
determining whether kinase inhibitors treatment blocks CML progression at least 
in part by suppressing exosome modulation of the leukemia bone marrow 
microenvironment. First, it was evaluated the effect of imatinib on exosome 
release by K562 CML cells and on angiogenesis induced by those exosomes 
and exosomes from treated cells. Imatinib has been reported to reduce VEGF 
release by K562 cells (263). It is able to decrease VEGF production in patients 
with CML, resulting in decreased bone marrow vascularity (292). These findings 
led to the conclusion that imatinib regulates bone marrow angiogenesis by the 
regulation of VEGF production. Here, it was demonstrated that imatinib also 
regulates exosome release. It was found that non-toxic drug concentrations 
effectively reduced exosome release by 58% from K562 cells. K562 cell line has 
been reported not to express c-kit (263), and PDGFR inhibitors did not affect cell 
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functions (293), so the decreased exosome release observed should be related 
to the BCR/ABL tyrosine kinase inhibitor activity of imatinib. It was also showed 
that exosomes released by K562 cells treated with imatinib maintained their 
ability to stimulate tubular differentiation by endothelial cells on Matrigel. This 
suggests that imatinib interferes with the mechanisms involved in exosome 
secretion but doesn’t change exosome composition. 
It was then studied the effect of imatinib on endothelial cells and on their ability to 
respond to exosome stimulation. It was found that treatment of HUVECs with 
imatinib for 48 h did not have toxic effects, even with concentrations above 
physiologically attainable plasma concentrations. This is in accordance with a 
previous report that describes the inability of imatinib to inhibit the normal 
endothelial cell function (294). Imatinib also did not affect HUVEC internalization 
of exosomes. Moreover, treatment of HUVECs plated on Matrigel with imatinib 
did not block exosome-stimulated tube formation. Surprisingly, imatinib itself 
induced increased tube formation at all the concentrations tested. This could be 
due to a response of the endothelial cells to the presence of the inhibitor resulting 
in activation of other pathways that cause stimulation of tubular differentiation. 
Dasatinib is a kinase inhibitor that has been shown be an effective therapeutic for 
imatinib-resistant CML. Dasatinib, in addition to inhibition of the fusion oncogene 
BCR/ABL, inhibits Src family kinases (SFKs), c-kit, PDGFR, and EphA2 (91, 93, 
295, 296). SFKs comprise a subset of non-receptor protein tyrosine kinases that 
includes c-Src, Fyn, Yes, Lyn, Lck, Hck, Blk, Fgr, and Yrk (268). Other than their 
ability to promote tumor growth and metastasis (268), SFKs coordinate multiple 
signaling pathways involved in regulating endothelial cell function, making SFKs 
targets for antiangiogenic therapy (297). A recent study reports that dasatinib 
suppresses tumor growth in vivo by inhibiting the recruitment and function of 
endothelial and myeloid cells, and SFK signaling in these cell types. Moreover, it 
is reported that dasatinib treatment inhibits HUVEC cell migration in response to 
VEGF and bFGF (267). 
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Figure 32. Proposed model of CML exosomes activity inside the bone marrow 
microenvironment. Exosomes released by CML cells stimulate increase in bone 
marrow vascularity. This is due, at least in part, to exosome internalization by endothelial 
cells and exosome trafficking through nanotubular structures. Exosome effects are 
modulated by imatinib through the inhibition of exosome release, and by dasatinib 
blocking both exosome release and angiogenesis stimulation. 
 
Our findings show that dasatinib, like imatinib, is able to reduce exosome release 
from K562 CML cells. This was expected, since dasatinib targets many of the 
same protein kinases inhibited by imatinib. Exosomes isolated from dasatinib 
treated K562 cells were still able to induce tube formation in vitro. However, in 
contrast to imatinib treatment, dasatinib exposure blocked tubular differentiation 
in HUVECs incubated with exosomes. This inhibition was not correlated to 
impaired exosome internalization. These results suggest that targeting SFKs is 
important for endothelial cell activation by CML exosomes. The above-mentioned 
finding was supported by data showing that exosome treatment increased 
phospho-c-Src levels, and that dasatinib inhibited c-Src activation stimulated by 
exosomes. 
The activation of c-Src as a consequence of exosome treatment is an important 
finding because Src can modulate angiogenesis in different ways. Src has been 
shown control expression of angiogenic growth factor and cytokines by regulating 
Discussion  
 
 76 
their gene expression (297). Src can induce up regulation of VEGF or IL-8 
expression (297, 298). Repression of Src down regulates the expression of these 
two factors resulting in decreased tumor vascular formation in vivo and in vitro 
(299, 300). Src can also elicit signaling in endothelial cells. Src can activate FAK, 
a protein that is involved in the control of cell motility and invasion (301). Here, it 
was showed that exosome treatment stimulated FAK phosphorylation at the site 
known to be phosphorylated by Src kinase (268). The levels of phosphorylation 
and the number of focal adhesions were reduced by dasatinib treatment. This 
indicates that dasatinib regulates FAK activity by selective inhibition of c-Src. 
This thesis suggests that dasatinib may also be active against CML because of 
its activity against c-Src, indicating Src as an important kinase for therapeutic 
intervention in CML. It has been recently reported that the c-Src inhibitor 
AZM475271 is able to inhibit tumor growth and metastasis of human pancreatic 
cancer in part for its anti-angiogenic activity (302). These new treatment could be 
proposed in association with imatinib to yield a more effective response against 
CML-associated angiogenesis. Alternatively, this compound could be 
administered in association with other drugs, especially in the case of resistance 
to the imatinib treatment. 
In conclusion, this thesis shows for the first time that exosomes released by CML 
cells stimulate vascular cytoskeletal reorganization. We have characterized the 
uptake and relocalization of exosomes in activated endothelial cells, and 
demonstrated for the first time cell-to-cell exosome transfer. We showed that 
imatinib reduce exosome secretion and dasatinib targets both CML cells and 
endothelial cell response to CML exosome stimulation. Overall, this study 
suggests exosomes as a new target for CML therapy. 
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